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The project consisted of two major sections
(i) A high performance liquid chromatography assay to determine 
total D-penicillamine in human plasma was developed and modified. 
The final system comprised two columns together with a switching 
valve, coupled with an electrochemical detector fitted with a 
sulphydryl-specific amalgamated gold electrode. The resultant 
chromatography was rapid, exhibited high sensitivity {<2.5 ng on 
column) and very reproducible rendering it suitable for pharmaco­
kinetic studies. The pharmacokinetics of the drug were studied
in normal volunteers and rheumatoid arthritis patients. Absorption 
of D-penicillamine was reduced when administered with food. The 
drug was rapidly absorbed from the gut reaching its peak plasma 
concentration at about two hours and exhibited two half-lives, 
an initial rapid decline (5-6 hours) followed by a slower terminal 
phase (55-60 hours). These results are discussed with regard to 
possible correlations between steady-state drug levels and clinic­
al efficacy and toxicity exhibited by D-penicillamine.
(ii)Successful therapy with D-penicillamine leads to an improvement 
in monocyte accessory function mediated, at least partially, by 
an effect of the drug on cell surface sulphydryl groups. The 
sulphydryl dependence of monocyte functions relevant to their 
accessory function as possible targets for D-penicillamine was 
investigated. Antigen presentation and Ca^* ion mobilisation 
were found to be unaffected by reversible blockade of cell mem­
brane sulphydryl groups by para-hydroxymercurisulphonic acid 
(pHMPSA). Sulphydryl blockade by this agent inhibited reacylation 
of free fatty acid but this effect was reversible by thorough
Vlll
washing of the cells. Oxidative metabolism of monocytes was 
abolished by pHMPSA treatment. However, monocytes from rheumatoid 
patients treated with NSAIDs and with D-penicillamine generated 
higher amounts of H^O^ than cells from control subjects. The 
relevance of these findings in relation to rheumatoid arthritis 




This thesis has investigated different aspects of the 
pharmacology of a sulphydryl-containing anti-rheumatic drug, 
D-penicillamine. The work undertaken has comprised two major areas:-
(i) The development of a high performance liquid chromatography 
(HPLC) system to measure D-penicillamine in plasma, and
(ii) The delineation of Sulphydryl-dependent monocyte functions 
which may represent possible targets for D-penicillamine in rheuma­
toid patients.
This has necessitated the following layout for the introduction.
First, there is a section (lA) on rheumatoid arthritis which discusses 
its pathology, iramunopathogenesis etc. This section terminates with 
the chemotherapy of rheumatoid arthritis which is not intended to 
provide a comprehensive review of the topic but merely to give a 
brief overview of non-steroidal anti-inflammatory drugs and second- 
line anti-rheumatic agents. Section IB is a detailed account of D- 
penicillamine, its pharmacology, use in rheumatoid arthritis and the 
development of assays to measure the drug. Finally, there is a section 
(1C) on the role of SH groups in the immune response and their observed 
disturbance in rheumatoid arthritis. This highlights a possible link 
between the aberrant immune response in rheumatoid patients and the 
immunomodulatory properties of sulphydryl-reactive anti-rheumatic 
drugs such as D-penicillamine. 
l.A. RHEUMATOID ARTHRITIS
The term rheumatoid arthritis (RA) describes a chronic inflam­
matory disorder of unknown aetiology which characteristically affects 
the synovial joints (Short et al, 1957). The articular inflammation 
may go into remission but generally continues to cause progressive 
joint destruction and deformity leading to varying degrees of dis­
ability. Extra-articular features such as nodules, vasculitis and
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splenomegaly which may accompany the joint symptoms emphasise the 
systemic nature of the disease. The most commonly affected joints 
are the proximal, interphalangeal and metacarpophalangeal joints, 
wrists, metatarsophalangeal joints and knees. The disease is about 
three, times more common in females than in males. Onset of the disease 
can occur at almost any age but peak incidence occurs between ages 
25-55.
In order to understand the pathological changes that occur 
in the joints in RA, it is necessary to describe the structure of 
normal synovial joints. 
l.A.l. SYNOVIAL JOINT STRUCTURE
Synovial or diarthrodial joints possess a joint cavity which 
permits them to be freely movable. Such joints are encompassed by 
a capsule consisting of a dense, fibrous outer layer (fibrosum) which 
diminishes towards the articular cavity giving way to a thin lining 
of synovial membrane. This membrane encapsulates the whole of the 
articular cavity except at those places where the ends of the opposing 
bones are covered by articular cartilage. The synovial cavity is 
filled with a highly viscous fluid which lubricates the joint sur­
faces. A diagrammatic representation of a typical synovial joint is 
shown in figure 1.
The synovial membrane is considered to consist of two basic 
layers. The innermost layer lining the synovial cavity,known as the 
intima,is predominantly cellular with an abundant blood supply. The 
intima lies upon a less vascular sub-synovial layer consisting of a 
meshwork of connective tissue. This can be mainly areolar, fibrous 
or fatty in its nature depending upon its location in the joint. The 
outer part of this sub-synovium merges with the fibrosum of the capsule.
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A = SYNOVIAL FLUID
B  = a r t i c u l a r c a r t i l a g e
C = FIBROUS CAPSULE 
D = SYNOVIAL MEMBRANE 
E = BONE
FIG.1 . Diagrammatical cross-section showing the structure 
of the typical synovial joint.
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The basic functions of the synovial membrane are the 
production of the synovial fluid and the removal of debris and 
foreign material from the synovial cavity. Microscopic studies 
of the intimai layer distinguish two major cell types (Ghadially 
and Roy, 1969). The predominant cell type, termed type A, is 
characterised by its large number of organelles including numerous 
lysosomes and vacuoles and small amount of endoplasmic reticulum.
These cells resemble macrophages in their characteristics being 
active in phagocytosis and secretion. In contrast, type B cells 
have few organelles and possess abundant endoplasmic reticulum.
These cells are thought to produce the hyaluronate of the synovial 
fluid. In addition there are some cells which share the features of 
both major cell types. These intermediate cells, termed AB cells by 
Ghadially (1983), suggest that type A and B cells are not distinct 
races of cells but merely represent different functional phases of 
the same basic cell.
Synovial fluid is essentially a dialysate of plasma to which 
hyaluronate has been added. This hyaluronate, produced by cells of 
the synovium, is a high molecular weight glycosamincglycan respons­
ible for the viscosity of the fluid and hence essential to its lub­
ricating properties. The fluid is normally clear and does not clot 
due to the absence of fibrinogen. It bathes the articular surfaces 
serving as a source of nutriment for the cartilage.
The articular cartilage covering the ends of opposing bones 
is the weight-bearing surface of the joint. In adults it is an 
avascular, alymphatic and aneural tissue composed of a small number 
of chondrocytes set in an abundant matrix. This matrix consists 
basically of a framework of collagen fibrils (mainly type II collagen) 
which entraps a ground substance rich in water and proteoglycans
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manufactured by the chondrocytes. The functions of articular 
cartilage depend upon its resilience and load-bearing properties. 
These are due to the osmotic pressure of water taken up by the 
proteoglycans retained and restrained by the network of collagen 
fibrils. (Ghadially, 1983). 
l.A.2. PATHOLOGY OF THE RHEUMATOID JOINT
Correct mechanical functioning of the joint depends upon 
maintenance of normal joint architecture. In RA, the normal struct­
ure of the joint becomes altered thus causing a disturbance in its 
normal function. This leads to the disability so characteristic of 
the disease, the degree of which is largely determined by the extent 
of joint damage.
It has been difficult to appraise the early lesions that occur 
in the rheumatoid joint since most patients do not present until the 
synovitis is quite well established. Also, synovectomies are not 
common, particularly in early RA. Amongst the earliest documented 
events are an increase in blood flow to the joint together with some 
oedema of the sub-synovium. Microvascular injury is evident as 
demonstrated by endothelial cell damage, gaps between the endothelial 
cells, thrombosis of small vessels and extravasation of erythrocytes. 
The synovial lining cells undergo a mild hyperplasia and, in some 
cases, there is a small degree of polymorphonuclear (PMN) cell in­
filtration into the superficial synovium and perivascular locations. 
The synovial fluid also contains small numbers of mononuclear cells.
As rheumatoid synovitis becomes established, the synovium under­
goes gross histopathological changes. There is substantial hyper­
trophy and hyperplasia of the synovial lining cells. The intima, 
normally only 1-3 cells deep, can reach thicknesses of up to about 
10 cells. Within the intimai layer there are multinucleated giant 
cells which are probably derived from type A cells (Ghadially and
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Roy, 1969). The hyperplasia seems to involve all the different 
synovial cell types but while Ghadially (1983) asserts that there 
is a predominance of type AB and B cells, other workers maintain 
that many of the hyperplastic cells appear to be the macrophage­
like type A cells (Meijer et al, 1977; Theofilopoulos et al, 1980).
The inflamed, oedematous synovium protrudes into the joint cavity 
as slight villous projections extending towards the articular cartil­
age.
There is extensive mononuclear cell infiltration of the normally 
acellular sub-synovial stroma. Sometimes these cells are collected 
into follicles particularly around smaller blood vessels although true 
germinal centres are rare. The dominant cell within such aggregates 
in the B-lymphocyte (Meijer et al, 1977; Janossy et al, 1981).
The majority of mononuclear cells within the rheumatoid synovium, 
however, are T-lymphocytes which account for up to 85% of the lympho­
cytes found there. (Meijer et al, 1977; Froland and Abrahamsen, 1979).
Along with the changes in cellular structure of the synovium, 
there is a concomitant increase in the volume of the synovial fluid 
which shows extensive cellular infiltration. The majority (75-90%) 
of these are PMN cells with the remainder consisting mainly of lympho­
cytes together with some monocytes, macrophages and synovial lining 
cells (Zvaifler, 1973). Plasma proteins such as fibrinogen which 
are normally excluded from synovial fluid are found within rheumatoid 
synovial fluid due to increased vascular permeability. Activation of 
proteins such as fibrinogen and plasminogen, to form fibrin and 
plasmin respectively, may be involved in articular inflammation 
(Zvaifler, 1973).
The normal capacity of cartilage to rebound from a deforming 
force is lost in the rheumatoid joint due to the loss of proteoglycans 
from the cartilage matrix (seen as a loss of metachromatic staining).
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Although most of the proteoglycan depletion occurs in regions where 
the inflamed synovium has encroached as pannus upon the cartilage 
surface, depletion is also seen at sites well removed from the ad­
vancing margins of the synovial membrane. Proteoglycan loss is 
probably a result of enzymatic digestion of the core protein of the 
proteoglycan subunit by proteases (Krane, 1979). Such proteases are 
found within the synovial fluid that bathes the cartilage.
Originally, the acid protease cathepsin D was proposed as 
the critical enzyme responsible for such damage (Fell and Dingle,
1963; Poole et al, 1976). Woessner, however, has demonstrated that 
this enzyme is only effective at acid pH^, (Woessner, 1974). Thus 
cathepsin D is unlikely to play an important role in extracellular 
digestion of proteoglycans since such low pH^ are not found in rheuma­
toid synovial fluids (Falchuk, Goetzl et al, 1970). Extracellular 
destruction of proteoglycans is likely to be caused by neutral pro­
teases such as those produced by human granulocytes characterised as 
an elastase and a chymotrypsin-like enzyme (Keiser et al, 1Q76). The 
activity of these enzymes is normally regulated by inhibitor proteins 
such as -macroglobulin and a^^-antitrypsin. These inhibitors are 
present within rheumatoid synovial fluids thus making it unlikely 
that grossly uncontrolled degradation occurs (Krane, 1979). Proteogly­
can loss may also be attributable to a depressed synthetic capacity 
of the cartilage in the inflamed joint. This inhibition may be due to 
soluble factors present in rheumatoid synovial fluid such as prosta­
glandins (Malemud and Solokoff, 1977).
Loss of proteoglycans from the cartilage is insufficient to 
cause irreversible structural damage since the skeletal framework 
is provided by collagen. Loss of collagen therefore is responsible
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for structural damage. The triple helical configuration of the 
collagen molecule imparts a resistance to proteolytic digestion 
by enzymes such as trypsin, pepsin and chymotrypsin (Harris and 
Krane, 1974). Formation of collagen fibrils further enhances this 
resistance.
It has been demonstrated that explants of rheumatoid synovial 
tissue in culture produce collagenases which are neutral metal pro­
teases able to digest collagen (Evenson, 1968). Proteolytic attack 
by these enzymes cleaves the collagen chains into two fragments 
which leaves the structure open to further digestion by other 
proteases (Harris et al, 1972).
The greatest destruction of connective tissue in the rheuma­
toid joint occurs where the invading pannus extends over the surf­
ace of the articular cartilage. Pannus is a fibro-vascular gran­
ulation tissue comprising connective tissue, small blood vessels, 
hyperplastic mesenchymal cells and various inflammatory cells, 
which arises from the perichondral synovial membrane (Zvaifler, 
1973). The cells in the pannus which are responsible for collag- 
enase production are large, nucleated cells which have dendritic 
processes but lack macrophage markers and are presumably syno­
viocytes. Collagenase and prostaglandin production by these syno­
viocytes is greatly enhanced by the cytokine, Interleukin-1,
(IL-1) which is produced by cells of the monocyte/macrophage lin­
eage in the pannus. (Mizel et al, 1981). The collagenase is re­
leased in an inactive form which can however bind to collagen 
fibrils (Werb et al, 1977). It is unclear whether this latent form 
of the enzyme is a true zymogen or the active enzyme complexed 
with an inhibitor (Krane, 1979); however, activation is achieved 
by the action of proteolytic enzymes produced by the cells of the
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pannus. Another possible activator of the latent collagenase which 
may be of considerable importance in vivo is plasmin since rheuma­
toid synovial cells produce plasminogen activator which converts 
plasminogen found in rheumatoid joints into plasmin. (Werb et al, 
1977). Plasmin may activate the inactive enzyme attached to coll­
agen fibrils thus initiating the destruction of collagen contain­
ing tissues. Plasminogen activators can also be produced by endo­
thelial cells of the small blood vessels in the pannus.
Once initiated,the collagenolytic process can be continued 
by enzymes produced by pannus cells such as cathepsin D which can 
degrade the collagen fragments produced by collagenase action. 
Collagen fibres are sometimes observed within phagolysosomes of 
cells within the pannus (Kobayashi and Ziff, 1975). Chondrocytes 
near the advancing edge of the pannus are able to replicate with­
in their lacunae and can be activated to secrete enzymes capable 
of degrading the cartilage matrix (Harris, 1979). Again, IL-1 
is able to induce such activity in the chondrocytes (Jasin and 
Dingle,1981). Collagen loss from the cartilage is essentially ir­
reversible since the chondrocytes have limited ability to regener­
ate the type II collagen (Krane, 1979).
In chronic, persistent RA there is characteristic erosion of 
the subchondral bone. Most of this damage is presumed to be caused 
by destruction by the pannus but some bone loss may also result 
from increased bone resorption by osteoclasts. The rheumatoid 
synovium may produce factors that possibly contribute to the en­
hanced resorptive activity such as prostaglandin (Robinson et al, 
1975) and osteoclast activating factor (Krane, 1979).
The destructive changes to the cartilage and bone are the 
major factors in causing disruption of joint function. Weaken-
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ing of the joint capsule and tendons can occur along with liga­
ment damage causing instability and subluxation. Fibrosis and 
ankylosis of opposing articular surfaces can occur in severe joint 
damage leading to decreased freedom of movement. 
l.A.3. EXTRA-ARTICULAR MANIFESTATIONS OF RHEUMATOID ARTHRITIS
Although essentially a disease affecting synovial joints, 
the systemic nature of RA is emphasised by the constitutional symp­
toms seen in the disease. These include general malaise, weight 
loss and fever (Eye, 1978). Some degree of anaemia is found in al­
most all rheumatoid patients, a finding common to most chronic in­
flammatory conditions (Turnbull, 1971). In addition, extra-artic­
ular manifestations can occur involving a number of other tissues 
of the body. The appearance of such features generally occurs in 
seropositive patients i.e. patients whose serum contains rheuma­
toid factor (RF), immunoglobulin directed against the Fc portion of 
IgG.
Probably the most common of these manifestations are subcut­
aneous nodules which appear at some time in about 20-25% of patients 
who are almost invariably seropositive. The nodules are firm mass­
es, varying in shape and size, within subcutaneous or deeper con­
nective tissues. Histologically, the rheumatoid nodule is com­
posed of a central area of necrosis surrounded by a palisade of 
epitheloid cells with variable degree of lymphocyte and plasma cell 
infiltration and vasculitis. The nodules may appear, disappear and 
reappear at any time. Although they rarely cause symptoms, they 
can break down and become infected.
A wide range of vasculitic lesions often occur in rheumatoid 
patients, generally in those patients with long-standing disease 
with high RF titres and nodules. Most of the lesions are often
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clinically benign such as those affecting the digital blood 
vessels characterised pathologiclaly by intimai proliferation. 
Rarely, some patients develop a vicious necrotising arteritis 
causing necrosis of the skin, digital gangrene, neuropathic les­
ions and visceral infarction which may lead to death. Fortunately 
this explosive arteritis occurs very infrequently and one or more 
of these manifestations can appear insidiously without necessarily 
being life-threatening. The pathogenesis of rheumatoid vasculitis 
is unclear though it is thought that deposition of circulating imm­
une complexes may play a prominent role. However, their exact 
relationship to vascular damage has yet to be fully understood. 
Other extra-articular features include scleritis, muscle wasting, 
lymphadenopathy and splenomegaly. Felty’s syndrome is a symptom 
complex in which RA is coupled with splenomegaly and neutropenia. 
It has been suggested that hypersplenism is the cause of the neutro­
penia but in some patients the neutropenic abnormality does not 
respond to splenectomy.
l.A.4. IMMUNOPATHOGENESIS OF RHEUMATOID ARTHRITIS
There is considerable evidence implicating both humoral and 
cell-mediated immunological processes in the pathogenesis of RA.
The rheumatoid joint shows substantial infiltration by lymphoid and 
phagocytic cells and interactions between these cells and their 
products are thought to contribute to the tissue destruction so 
characteristic of RA. Within the synovium, lymphocytes, plasma 
cells and macrophages are found in both diffuse and nodular patt­
erns, an arrangement which has been likened to an antigenically 
stimulated lymph node (Gardner et al, 1965).
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l.A.4.(1) HUMORAL IMMUNITY
In RA, serum immunoglobulin levels are raised whilst at the 
major site of inflammation, the rheumatoid synovium, there is 
generation of large amounts of immunoglobulin. About 25% of the 
immunoglobulin found in the synovial fluid is synthesised by the 
lymphocyte infiltrate of the synovial pannus (Sliwinski and 
Zvaifler, 1970). Excised rheumatoid synovium has also been shown 
to produce immunoglobulin in vitro (Smiley et al, 1968). These 
studies however did not define the antigenic specificity of the 
antibody produced. One study using synovial explants from RA 
patients previously immunised with tetanus showed the production of 
only very small amounts of specific anti-tetanus antibody. One 
reason for this might be that lymphoid cells of the rheumatoid syno­
vium are immunologically committed to another antigen prior to 
tetanus challenge (Herman et al, 1971).
Egeland and colleagues have shown the proportions of immuno­
globulin produced in the synovium to be IgG, 48%, IgM, 18%, and 
IgA, 34% (Egeland et al, 1982). Interestingly, IgG produced by the 
synovium shows a restricted electrophoretic mobility with consider­
able enrichment of the IgG-3 subclass (Munthe and Natvig, 1972; 
Hoffman et al, 1982; Smiley et al, 1985). Some studies have also 
found an increased incidence of light chains (Lindstrom 1970, Munthe 
and Natvig, 1972). Such restricted responses might indicate a 
selective stimulation of the RA synovial lymphoid infiltrate (Smiley 
et al, 1985).
The major humoral immune reaction in RA is the production of 
rheumatoid factors (RF’s) i.e. auto-antibodies directed against 
the Fc region of IgG molecules. RF’s are found in the IgG, IgM and 
IgA classes (Johnson and Faulk, 1976). It is important, however.
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to note that RF’s are not specific for RA as they can be found in 
the serum of patients with other rheumatic diseases such as SUE, 
non-rheumatic diseases such as bacterial endocarditis as well as in 
that of some normal individuals (Carson, 1982). In serum, IgM RF 
may react with IgG to give complexes with a sedimentation coeffic­
ient of about 22S which are probably cleared by the reticulo-endo- 
thelial system (Paget and Gibofsky, 1979). IgG RFs can obviously 
self-associate to form intermediate-sized complexes, the presence 
of which has been demonstrated in the rheumatoid synovium of both 
seropositive and seronegative patients with active disease (Munthe 
and Natvig, 1972). Such complexes may play an important role as 
inflammatory stimuli in rheumatoid synovitis (Munthe and Natvig,
1972; Male and Roitt, 1981). Both IgM RF and IgG RF can fix com­
plement (Tanimoto et al, 1975; Brown et al, 1982) whilst IgG-IgG 
RF complexes can stimulate local production of RFs and other immuno­
globulins in the synovium (Chattopadhyay et al, 1979; Egeland et al, 
1982). Complexing of these immunoglobulins may also impair negative 
feedback upon plasma cell antibody production causing a perpetuation 
of the immune response and inflammation (Natvig and Munthe, 1975).
One possible explanation for RF production is the alteration of auto­
logous IgG leading to enhanced immunogenicity. It has been suggested 
that free radicals generated by activated neutrophils can alter the 
structure of IgG (Lunec 1984).
The pathogenic importance of RF in RA remains controversial. 
Synthesis of RF undoubtedly occurs in the rheumatoid synovium but 
whilst early studies indicated that about 60% of synovial IgG pro­
ducing plasma cells produced RF (Smiley et al, 1968), more recent 
evidence shows very few synovial plasma cells synthesising RF
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 ̂ (Egeland et al, 1982). Such observations might argue against any 
significant pathogenic role for RF in articular inflammation. 
Recently, an immunoregulatory role has been proposed for RFs as 
anti-idiotypic antibodies directed against anti-bacterial pepti- 
doglycan antibodies (Johnson, Phua and Evans, 1985).
Whatever the specificity of antibodies produced by rheuma­
toid synovial lymphoid cells, one of the main postulates concern­
ing the pathogenesis of inflammation in RA is the formation of 
immune complexes in the joints (Zvaifler 1973). Immune complexes 
(ICs) can cause activation of the complement cascade and comple­
ment fragments are demonstrable in rheumatoid synovial fluid. Com­
plement levels, whilst apparently normal in the serum of rheuma­
toid patients, are reduced in the synovial fluids of most patients 
correlating inversely with IC levels (Luthra et al, 1975). Local­
isation of immunoglobulin and complement in articular cartilaginous 
tissues has been demonstrated in the majority of RA patients (Cooke 
et al, 1975). Complement fragments C3a and C5a are chemotactic 
for PMNs and so would help promote the influx of these cells into 
the rheumatoid synovium. These neutrophils, together with synovial 
pannus macrophages, phagocytose the complexes with concomitant re­
lease of hydrolytic enzymes capable of causing articular damage 
(Zvaifler, 1973). Activation of complement by proteolytic enzymes 
present in rheumatoid synovial fluid may be important in perpet­
uating the inflammatory response (Mellbye et al, 1983). Engulf- 
ment of ICs also causes the phagocytic cells to release oxygen- 
derived radicals (ODRs). The term oxygen-derived radicals here 
describes superoxide anion C^'", hydroxyl radical OH', hydrogen 
peroxide H^Og and singlet oxygen ^0^ although chemically only 
.0^ and OH' are strictly radicals. ODRs have been implicated
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as possible mediators of tissue damage in chronic inflammation. 
Goldstein et al, (1976), have shown that C5a induces ODR release 
from neutrophils independent of phagocytosis. ODRs have been shown 
to damage cultured endothelial cells (Weiss et al,1981; Niwa et al, 
1982) and the phagocytic cells which had produced them (Sweder 
von Asbeck et al, 1984). Niwa and colleagues (1983) have demon­
strated that ODRs released by synovial fluid neutrophils can de­
press the reactivity of synovial fluid lymphocytes in RA perhaps 
explaining their disturbed immuno-reactivity. In vitro studies have 
also shown that ODRs cam damage hyaluronic acid (McCord, 1974; 
Monboisse, Braquet and Borel, 1984). ODR-induced depolymerisation 
of hyaluronic acid may cause the reduction in synovial fluid vis­
cosity seen in inflamed joints (Greenwald and Moy, 1980). Much 
attention has focussed on ODR-induced lipid peroxidation as a mech­
anism by which ODRs can cause tissue damage (Kellogg III and 
Fridovich 1975; Kellogg III and Fridovich 1977; Dixit, Mukhtar and 
Bickers 1982). Both the hydroxyl radical (OH*) and singlet oxygen 
(^0^) can mediate lipid peroxidation (Badwey and Karnovsky, 1980). 
Polyunsaturated fatty acids are particularly susceptible to lipid 
peroxidation which can lead to the formation of low molecular weight 
aldehydes and alkenes etc. This may cause severe disruption of the 
cell membrane structure an4 possibly, cell death. Peroxidation 
of cell membrane lipids has been shown to be able to influence 
arachidonate metabolism (Cook and Lands, 1976). Cleland (1984) 
has suggested that in this way ODRs derived from phagocytic cells 
may influence the metabolism of adjacent cells within an inflam­
matory focus.
The increased levels of lipid peroxidation products found 
in rheumatoid synovial fluid suggests that this reaction might be
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important in causing tissue damage in RA (Lunec et al,1981 ; Rowley and 
Halliwell,1983). The formation of OH* radicals from 0^” and req­
uires the presence of transition metal ions, usually iron (Gutteridge, 
Rowley and Halliwell,1982). In active RA there is increased iron dep­
osition in the synovium (Blake et al,1983) and iron complexes may cat­
alyse OH* formation in synovial fluid (Rowley et al,1984). Iron cataly­
sed OH* formation and lipid peroxidation are inhibited by the iron-che- 
lator desferrioxamine. The ability of this chelating agent to suppress 
inflammation in animal models (Gutteridge,Richmond and Halliwell,1979; 
Blake et al,1983) further implicates iron-catalysed OH* radical format­
ion and, possibly, lipid peroxidation in mediating tissue damage. Rec­
ently it has been shown that administration of intravenous dextran-iron 
to RA patients to treat anaemia causes a flare-up in synovitis together 
with an increase in lipid peroxidation products in the synovial fluid
(Blake et al, 1985).
l.A.4.(ii) CELL MEDIATED IMMUNITY
An increasing number of observations suggest that cell mediated 
immunity plays an important role in the pathogenesis of RA. Indeed, in 
congenitally agammaglobulinaemic boys there is an increased incidence of 
RA in which immune complexes are, presumably, of no importance (Taussig, 
1979). Similarly, a chronic arthritis may be induced in bursectomised 
chickens (Dumonde,1971). In the rheumatoid synovial membrane the predom­
inant infiltrating cell is the T-cell (Abrahamsen et al,1975) while 
rheumatoid synovial fluid and supernatants of rheumatoid synovial tissue 
show T-cell derived lymphokine activity (Stastny et al, 1975).
A number of studies have shown impaired T-cell function in 
RA. Some patients show depressed cutaneous hypersensitivity to 
recall antigens (Waxman et al, 1973) and several studies have dem­
onstrated significantly depressed in vitro lymphocyte activation 
by T-cell dependent antigens, phytohaemagglutinin (PHA) and con- 
canavalin A (Con A) with respect to normals (Griswold and
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McIntosh, 1973; Lance and Knight, 1974; Highton et al, 1981).
Although the synovium is the major site of inflammation in 
RA it is not easy to obtain mononuclear cells from it and normal 
cells cannot be obtained for control purposes. Consequently, studies 
of the immune response in rheumatoid arthritis have had to use in 
vitro culturing of peripheral blood mononuclear cells since such 
cells can be obtained easily from both RA patients and control sub­
jects. The most common methods utilised for analysing immunoreg- 
ulation in vitro are measurement of lymphocyte proliferation in res­
ponse to mitogens such as PHA and ConA, and, measurement of Pokeweed 
mitogen(PWM) stimulated immunoglobulin production using an enzyme 
linked immunosorbent assay (ELISA). Whilst some studies have shown 
a normal proliferative response by RA cells (Reynolds and Abdou,
1973; Mnsella, 1974), others have demonstrated lower responses 
than in normals (Griswold and McIntosh, 1973; Lance and Knight,
1974; Highton et al, 1981). Such discrepancies may be attributable 
to patient heterogenicity and differences in the techniques employed 
by the investigators.Some workers have suggested that decreased res­
ponses are peculiar to particular subsets of patients e.g. those 
characterised by the presence of erosive joint disease (Silverman 
et al, 1976) and those that display anergic delayed hypersensitivity 
in vivo (Malone et al, 1984). Immunoglobulin production by rheuma­
toid cells has been shown to be lower than controls (Alarcon et al, 
1982; Poikpnen et al, 1982; Plater-Zyberk et al, 1983). McKeown 
et al (1984a)have shown that RA patients on non-steroidal anti­
inflammatory drugs (NSAIDs) show defective immunoglobulin product­
ion in vitro, those on penicillamine therapy show normalised res­
ponses (this will be discussed later in section 1.C.3).
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The hyporesponsiveness of rheumatoid mononuclear cells 
in vitro suggests defective immunoregulation in the disease. Such 
hyporesponsiveness may seem paradoxical in view of the apparent 
hyperactivity of the immune response in RA e.g. enhanced circulat­
ing levels of immunoglobulin. One possible explanation for this 
is that pre-activation of the cells in vivo renders them unable to 
be triggered fully in vitro.
Regulation of the immune response is achieved in part by the 
release of soluble mediators called cytokines produced by mononuc­
lear cells. Recent evidence has indicated imbalances in the pro­
duction of cytokines in RA which may be relevant to the immuno- 
pathogenesis of the disease. In response to antigens/mitogens and 
other stimuli, cells of the monocyte lineage produce a 12,000- 
15,000 MW factor called interleukin-1 (IL-1) (Mizel et al, 1981; 
Oppenheim and Gery, 1982). This induces T-cells to produce another 
cytokine, interleukin-2 (IL-2) (Smith et al, 1980) necessary for 
the proliferation of T-cells (Morgan et al, 1976). IL-2 synthesis 
leads to the production of gamma-interferon ( T-IFN) by T-cells 
(Torres, Farrar and Johnson, 1982) another cytokine which regulates 
the immune response. In addition to its effects on lymphocytes, 
IL-1 possesses many biological activities suggesting perhaps that 
it is more than a single molecule (Oppenheim and Gery, 1982). It 
is now widely accepted that IL-1 is probably identical to the fever 
inducing endogenous pyrogen and leucocyte endogenous mediator (LEM) 
(Szte.in et al, 1981) a factor which induces hepatocytes to syn­
thesise acute phase proteins (Kampschmidt, 1978).
IL-1 production has been demonstrated in the rheumatoid syn­
ovium (Mizel et al, 1981; Wood et al, 1983). IL-1 has several act­
ivities relevant to the pathological changes seen in the rheumatoid
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joint; it causes collagenase and prostaglandin secretion by syno­
viocytes (Mizel et al, 1981), the proliferation of fibroblasts 
(Schmidt, 1981) and induces chondrocytes to degrade the cartilage 
matrix (Jasin and Dingle, 1981). Disturbed cytokine production may 
be a significant factor in the pathogenesis of RA. Peripheral blood 
monocytes obtained from RA patients have recently been reported to 
produce significantly more IL-1 than cells from healthy controls 
(McKeown et al, 1984b;Tan et al, 1984; Nouri et al, 1985a).
Despite this increased IL-1 production, somewhat paradoxically, 
maybe peripheral blood mononuclear cells from RA patients show def­
icient IL-2 production when compared to normal cells (McKeown et al, 
1984b;Miyashaka et al, 1984; Nouri et al, 1985b, Combe et al, 1985). 
Stimulated T-lymphocytes express the Tac antigen which is the IL-2 
receptor (Uchiyama et al, 1981). Decreased expression of this anti­
gen has been reported on rheumatoid T-cells (Pirzad et al, 1985) 
correlating well with the finding that expression of Tac antigen is 
regulated by IL-2 itself (Weite et al, 1984).
The apparent hyporeactivity of T-cells in rheumatoid patients 
is supported by the finding of depressed IL-2 production. Indeed, 
this hyporeactivity has been attributed,at least in part, to def­
ective IL-2 production since addition of exogenous, recombinant 
IL-2 has been reported to correct the depressed autologous mixed 
lymphocyte reaction (AMLR) in RA (McKenzie, Mills and Panayi, 1985). 
Combe et al (1985) have suggested that depressed IL-2 production 
may lead to defective T-suppressor cell activity in the rheumatoid 
joint since they have also demonstrated deficient IL-2 production 
by RA synovial lymphocytes. This same study also showed defective 
T-IFN production in response to IL-2 by rheumatoid T-lymphocytes.
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Decreased T-IFN production by rheumatoid T-lymphocytes has also been 
reported by Hasler et al (1983) who attributed it to the inhibitory 
effects of monocyte-generated prostaglandins. However, Combe and 
his colleagues (1985) have shown that removal of the adherent cells 
does not alter the T-IFN production suggesting that excessive pro­
staglandin production is not responsible for the decreased T-IFN 
production. These workers suggest that T-cell hyporeactivity with 
respect to IFN and IL-2 production may cause B-cell hyperactivity 
with the resultant immunological injury seen in the rheumatoid joint.
The importance of immune mechanisms in RA is emphasised by the 
observed clinical improvements by immunosuppressive regimens of 
therapy. Thoracic duct drainage (Paulus et al, 1977), total lymph­
oid irradiation (Kotzin et al, 1981) and leukapheresis (Lockwood,
1979) often cause a remission in disease activity whilst use of 
immunosuppressive drugs, such as corticosteroids and cytotoxic drugs 
e.g. azathioprine, often has the same result. However, the general­
ised immunosuppression in RA patients as a consequence of this ther­
apy leaves them susceptible to infections, so caution is indicated. 
l.A.5. AETIOLOGY OF RHEUMATOID ARTHRITIS
Despite many years of intensive research, the aetiology of 
RA remains obscure. The generally accepted view is that RA arises 
out of a deranged regulation of the immune response to an antigenic 
stimulus in a genetically susceptible host. This can be viewed 
in two basic ways; firstly, an inability to eradicate the offending 
antigen such that it persists leading to chronic immunity, and, 
secondly, a failure to regulate the immune response after a normally 
transient stimulation by antigen (Paget and Gibofsky, 1979). Al­
though the identity of the antigen is still unknown, a microbial in­
fection remains an attractive proposition. However, as yet, no firm
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microbiological evidence has been produced to sustain such a view. 
Circumstantial evidence favouring this idea however is available. 
Chronic arthritis can accompany a number of natural and experiment­
ally-induced infections in animals e.g. pannus formation along with 
other features of rheumatoid synovitis are seen in some streptococ­
cal infections of rabbits (Paget and Gibofsky, 1979). Bacteria can 
cause some forms of arthritis e.g. infection by S .aureus (Phillips, 
1982). Studies to isolate bacteria from Rheumatoid synovial tissue 
has met with little success (Phillips, 1982).
Lyme disease, a systemic, inflammatory disorder also causes 
some changes in the synovium similar to those seen in RA (Steere 
et al, 1977). This disease is now thought to be transmitted by the 
tick Ixodes damini (Steere and Malawista, 1979) which carries the 
presumed infective agent, a spirochaete (Burgdorfer et al, 1982).
Perhaps more likely candidates are viruses and particular 
interest has been expressed in a role for infection by Epstein- 
Barr Virus (EBV). This is based on the high incidence of antibodies 
in RA patients directed against nuclear antigens (RANAs) found in 
EBV-transformed lymphoblastoid cell lines (Alspaugh and Tan, 1976; 
Alspaugh et al, 1978). This antibody was found in 67% of RA pat­
ients compared with only 8% of normals in these studies. A later 
study by Ng and colleagues (1980) found anti-RANA activity in more 
than 90% of both seropositive and seronegative patients as opposed 
to 16% of normals but the specificity of the assay utilised has been 
challenged (Catalano et al, 1980).
Lymphocytes from RA patients are stimulated by EBV, a poly­
clonal B-cell activator, to produce more IgM-RF than control lympho­
cytes (Alspaugh et al, 1978). The same study also demonstrated that 
RA lymphocytes transformed more spontaneously (without EBV) and
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showed more rapid transformation by EBV than normal cells.Since 
T-cells can suppress EBV transformation of animal cells these 
results might indicate defective T-cell function at least in 
vitro in RA (Bardwick et al, 1980). The idea that RA is initiated by 
some sort of polyclonal B-cell activator such as EBV causing dis­
turbed IgG production,including auto-antibodies such as RE, is 
quite an attractive one. However, the rather restricted nature of 
the immunoglobulin produced in RA (Smiley et al, 1985) would argue 
against such a suggestion. 
l.A.5.(i) IMMUNOGENETICS
The idea of some form of genetic predisposition to RA has 
been mooted for a long time but it is only since the discovery of 
an association between antigens of the major histocompatibility 
complex (HLA antigens) and certain diseases that this suggestion 
has had any firm basis. The important contribution that genetics 
can make to rheumatology was first demonstrated by Brewerton et al 
(1973) who showed a strong association between HLA-B27 and ankylos­
ing spondylitis. Recently it has been shown that RA is associated 
with an increased incidence of HLA-DR4 and DW4 in whites (Stastny, 
1978). Interestingly, the increased incidence is not seen in sero­
negative RA (Stastny, 1978). The exact nature of the link between 
these antigens and the pathogenesis of RA is uncertain; however, 
since DR products are expressed on macrophages, activated T 
lymphocytes and B-lynphocytes (Winchester and Kunlcel, 1979) and 
are involved in immunoregulation then DR-4 positive cells in RA 
patients might lead to an aberrant response to particular antigen(s). 
Recent evidence has suggested that DR-4 is associated with disease 
severity as opposed to pre-disposition (Jones et al, 1983) agree­
ing with the observation that patients with severe RA and extra-
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articular manifestations are almost invariably HLA-DR4 positive 
(Dinant et al, 1980).
l.A.6. CHEMOTHERAPY IN RHEUMATOID ARTHRITIS
While the exact cause remains unknown,treatment of RA with 
drugs continues to be empirical. Such therapy usually follows a well- 
established regimen. Initially, non-steroidal anti-inflammatory 
drugs (NSAIDs) are used to achieve pain relief and some reduction in 
the inflammation thereby allowing better joint function and improv­
ing the patient's general well being. In cases of less active dis­
ease NSAID therapy alone is often adequate. If the disease remains 
aggressive so-called "second-line anti-rheumatic" agents such as 
gold and penicillamine may be used in an attempt to suppress dis­
ease activity. In some cases these drugs appear to halt the prog­
ression of the disease so preventing further disability. However 
treatment with these drugs is hampered by the manifestation of toxic 
side-effects which has limited their widespread use. In extremely 
severe cases the use of cytotoxic/antimetabolic drugs and/or cortico­
steroid therapy may be considered in an effort to suppress immune 
activity in RA, thus, hopefully curbing the disease process. The 
nature of these agents means there are obvious problems with toxicity 
and generalised immunosuppression which severely restricts their 
application.
Non-steroidal anti-inflammatory drugs
NSAIDs do not appear to have any profound effects upon the under­
lying disease process in RA and so do not reverse the arthropathy. 
However, by virtue of their analgesic and anti-inflammatory effects 
they are of benefit clinically since this permits better joint function 
in reducing pain, stiffness and swelling. Aspirin and the salicylates 
have been used for a long time whilst newer classes of NSAIDs such as
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derivatives of the organic acids, proprionic acid (ibuprofen) and 
acetic acid (indomethacin), have been developed in recent years.
Their anti-inflammatory action is proposed to be due to the 
inhibition of the synthesis of prostaglandins (PCs) (Vane, 1971).
The PCs are a family of biologically active compounds derived from 
unsaturated fatty acids (generally arachidonic acid) by the action 
of the enzyme cyclo-oxygenase. This enzyme converts arachidonic 
acid into prostaglandin (PG) G^ which can be reduced to form PGH^. 
PGG^ and PGH^ are short-lived endoperoxides which undergo rapid 
enzymatic converstions to the prostaglandins (PGD^, PGE^ and 
PGI^) and thromboxanes (TXA^, TXB^). The PGs are involved in pro­
ducing the cardinal signs of inflammation - they are vasodilatory 
and pyretic and synergise with other inflammatory mediators e.g.
C5a and bradykinin to produce oedema and pain (Ninneman, 1984).
NSAIDs directly interact with cyclo-oxygenase to inhibit 
PG synthesis which accounts for their anti-inflammatory actions.
All NSAIDs show this inhibitory action in vitro although their 
potencies vary greatly (Crook et al, 1976). The variation in their 
potency does not correlate, however, with their rather equivalent 
clinical efficacy suggesting perhaps that their action may be more 
than simple inhibition of PG synthesis. Such a view is also sus­
tained by the inability of aspirin to produce noticeable anti­
inflammatory effects in rheumatoid synovial tissue at a dose (600 
mg./day) which totally abolishes cyclo-oxygenase activity.
In addition to their inflammatory actions, a number of studies 
have shown that PGs may have immunomodulatory properties. Thus 
PGE^ can suppress a number of T-lymphocyte functions at least in 
vitro including mitogen responsiveness (Goodwin et al, 1977) and 
IL-2 production (Rappaport and Dodge, 1982). Recent evidence has
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also shown that human B cell activation may be regulated by PGE^ 
(Staite and Panayi, 1982; Jellinek et al, 1985). In all these 
studies PGE^ has been demonstrated to have such effects at physio­
logically relevant concentrations. So, by inhibiting PGE^ synthesis, 
NSAIDs may also exert an immunomodulatory effect which may be rele­
vant to their mode of action in the treatment of RA. However NSAIDs 
do not have any profound effect upon the rheumatoid process making 
it unlikely that PGE^ modulation of the immune response plays a major 
role in the pathogenesis of this disease.
Second-line anti-rheumatic drugs
A number of drugs have been shown to be effective in the treat­
ment of RA by clinical experience despite lacking any direct anti­
inflammatory properties (Huskisson, 1976). These drugs including 
gold, penicillamine and anti-raalarials viz. hydroxychloroquine differ 
from the NSAIDs in that they appear to affect the progress of RA. 
Clinical effect with these agents only becomes apparent after a delay 
of several weeks, and, often, months which has led to their descript­
ion of "slow-acting". Additionally, inflammation may continue to be 
quiescent for some time after discontinuation of therapy. Although 
sometimes called "remission-inducing" drugs, total clinical remission 
with them is an extremely rare event and perhaps it is better to 
describe their action in RA as suppressive. Their therapeutic use 
has been somewhat hampered by their ability to induce toxic side- 
effects which can be life-threatening in some cases e.g. thrombo­
cytopenia and neutropenia. The major second line drugs used are 
gold salts and penicillamine and in this introduction only these 
agents are discussed.
Gold Compounds
Gold salts have been used in the treatment of RA since the
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1920s, their introduction being based on their anti-tuberculosis 
effect in the belief of a link between tuberculosis and RA. Despite 
initially favourable results it was not until I960 that the first 
controlled clinical trial established the efficacy of chrysotherapy 
(Research sub-committee of the Empire Rheumatism Council, I960).
The mechanism(s) by which gold compounds work in RA is obscure. 
Explanations based on biochemical effects observed in some model 
systems have included inhibition of the activity of lysosomal and 
other enzymes (Persellin and Ziff, 1966), interference with complement 
activation (Burge et al, 1978) as well as various non-specific anti­
inflammatory effects (Vernon-Roberts,1979). The disease modifying 
nature of the compounds however suggests a more profound immunomodul­
atory action. Lipsky and Ziff (1977) showed that gold sodium thio- 
malate (GST) inhibits the antigen/mitogen-induced proliferation of 
normal human blood mononuclear cells in vitro by interfering with 
monocyte function which is essential for such proliferation (Rosen­
berg and Lipsky, 1979a,b). They demonstrated that the gold atom it­
self inhibited monocyte function as opposed to thiomalate since GST 
and gold chloride were effective as inhibitors whilst thiomalate 
per se was not. These results suggest that gold compounds might 
work in RA by an immunosuppressive effect upon monocytes affecting 
their function in both initiation and expression of the chronic, 
immunologically mediated inflammatory reaction (Lipsky, 1982). How­
ever, it should be noted that many second-line anti-rheumatic agents 
contain thiol groups or are converted to thiol groups in vivo 
(Hunneyball, 1980) suggesting a role for the thiol moiety of GST. 
Indeed,it has been pointed out that all the gold salts used in con­
trolled long-term trials have been thiols (Munthe et al, 1978). 
Therefore it may be that GST has two active moieties involved in
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the mechanism(s) by which it works, the gold atom and the thiol 
group. The role of thiol groups in RA and second-line anti-rheuma­
tic agents is more extensively discussed in section l.C.
Gold has a number of side-effects which limits its use in 
rheumatoid arthritis. The most common side-effect with chrysotherapy 
is a rash occurring early after the commencement of treatment in 
about 30% of patients. Proteinuria can occur later in therapy and 
may necessitate withdrawal of the drug. Potentially more serious 
toxic reactions sometimes occur such as agranulocytosis, thrombo­
cytopenia and aplastic anaemia. Fortunately, however, such side- 
effects are rare. 
l.B.D-PENICILLAMINE
Penicillamine was first identified by Abraham and colleagues 
in 1943 as a penicillin-hydrolysis product during studies to eluci­
date the structure of penicillin. Penicillamine is a thiol-contain­
ing amino-acid similar in structure to the naturally occurring amino- 
acid, cysteine (see fig. 2 ). Walshe’s speculations that the
compound might be therapeutically useful in Wilson’s Disease (hepato­
lenticular degeneration) (Walshe, 1956), and cystinuria, an inherited 
disorder of amino-acid transport (Crawhall et al, 1963) were sub­
sequently proved correct. As with Wilson's Disease, the chelating 
properties of the drug have caused it to be used successfully in the 
treatment of some forms of heavy-metal poisoning including lead poison­
ing (Goldberg et al, 1963) and mercury poisoning (MacGregor and Clark­
son, 1974). Recently it has been used in a number of other condit­
ions such as chronic active hepatitis (Stern et al, 1977) and primary 
biliary cirrhosis (Dickson et al, 1977) although its efficacy in 
these conditions is, as yet, questionable. A list of therapeutic 

















FIG.2 . Comoarison of the structures of D-penicillamine 
and L-cysteine.
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TABLE 1 THERAPEUTIC APPLICATIONS OF PENICILLAMINE 
(established, discarded or under test)
Adapted from Lyle (1979)
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In I960, Ritzman, Coleman and Levin demonstrated the ability 
of penicillamine to dissociate macroglobulins in vitro due to dis­
ulphide bond cleavage. Two years later, Jaffe assumed that penicill­
amine might act similarly upon macroglobulin rheumatoid factor (RF) 
in patients with RA. Injection of the drug into the knee joint 
caused a reduction in the synovial fluid RF titre but no relief of 
symptoms (Jaffe, 1962). However, systemic administration of the 
drug did bring about a lowering of the serum RF after a few months 
treatment with prior clinical improvement being evident. Cessation 
of the treatment led to an increase in RF levels to pre-treatment 
levels but this did not occur until after many weeks (Jaffe, 1965). 
In subsequent years a number of groups carried out studies which 
confirmed Jaffe’s observations (Miehlke and Kohlhardt, 1967; Golding 
et al, 1968). Thus, penicillamine was demonstrated to produce a 
clinical improvement in RA although such effects were manifest only 
after a latent period of several weeks. However, the degree of res­
ponsiveness to the drug varied greatly amongst the patients with 
some responding dramatically and others showing little or no improve­
ment with the drug. Another striking aspect was the incidence of 
adverse reactions associated with the drug in RA patients ranging 
from mild skin rashes to more severe effects such as leucopenia.
In 1973, results from a multicentre trial confirmed the efficacy of 
the drug in RA but again provided evidence of its ability to induce 
adverse reactions (Andrews et al, 1973).
Commencement of penicillamine therapy in a rheumatoid patient 
follows generally the same indications for the employment of chryso­
therapy. Thus, patients whose disease is sufficiently active and 
who have failed to respond to treatment with non-steroidal anti­
inflammatory drugs are candidates for treatment with penicillamine.
—30—
The drug frequently not only leads to an amelioration of symptoms 
but also brings about an improvement in serological correlates of 
disease activity such as titres of rheumatoid factor and erythrocyte 
sedimentation rate (ESR). The drug, together with other second-line 
agents such as gold, also appears to be able to prevent further eros­
ions of peri-articular bones (Gibson et al, 1976). 
l.B.l. POSSIBLE MECHANISMS OF ACTION OF PENICILLAMINE IN RA
The chemical reactions of D-penicillamine (see later, p 35 ) 
clearly explain its action in conditions such as Wilson’s Disease and 
cystinuria. However, in RA the mechanism(s) by which D-penicillamine 
acts is far from clear. It is pertinent to ask whether its mode of 
action can be explained by its chemical reactions.
In active RA, levels of serum copper and caeruloplasmin are 
elevated but fall to normal upon suppression of disease activity by 
ACTH, aurothiomalate or penicillamine (Scudder et al, 1978). Jayson 
et al (1976) have shown that serum copper and caeruloplasmin are 
similarly raised in ankylosing spondylitis. Since penicillamine 
has no effect in this disease then it is unlikely to act in RA mere­
ly by promoting copper loss although it has been shown to increase 
copper excretion (Lyle et al, 1977). However, detachment of copper 
from protein-bound sites by the drug causes copper to form complexes 
of varying stability and mobility and such copper redistribution 
might be of importance in the inflammatory process.
The relationship between serum levels of other trace metals 
and D-penicillamine therapy in RA have been studied e.g. Zinc 
(Aasethet al, 1976; Jepsen et al, 1984). Whilst alterations in 
zinc levels are seen, the studies indicate that penicillamine does 
not act in this way in exerting its clinical effects.
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Another possible mode of action of D-penicillamine is the 
scavenging of oxygen derived radicals (ODRs) produced in the syno­
vium by phagocytic cells. ODRs have been increasingly implicated 
in the inflammatory process and can cause effects relevant to RA 
e.g. depolymerisation of hyaluronic acid (McCord, 1974), as out­
lined earlier in section l.A.4. The hydroxyl (OH*) radical, gener­
ally considered to be the most reactive of these species, is formed 
from superoxide anion 0^” and H^O^ in the presence of transition 
metal ions, generally iron. (Gutteridge, Rowley and Halliwell, 1982) 
The chelate that D-penicillamine forms with copper has been reported 
to have potent superoxide dismutase activity, thus removing the 0^* 
necessary for OH* formation, and can prevent depolymerisation of 
hyaluronic acid (Greenwald and Moy, 1980) which might account for 
some of the beneficial effects seen with D-penicillamine. Chelation 
of the, iron that catalyses OH* formation may also protect the joint 
from the destructive effects of these radicals. However, it should 
be remembered that chelation of iron by D-penicillamine is relatively 
poor in comparison with that seen with copper or lead ions (Doornbos 
and Faber, 1964) so such a mechanism is questionable. ODRs can also 
inactivate serum -proteinase inhibitor resulting in the loss of 
its inhibitory effect upon lysosomal proteinases (Carp and Janoff,
1980). Skosey and Chow (1982) have shown that D-penicillamine can 
protect the enzyme’s inhibitory capacity against the effects of 
neutrophil derived free radicals and those derived by a cell-free 
system i.e. xanthine oxidase acting upon acetaldehyde. This again 
might be relevant to a chelating and scavenging^ction for D-penicil- 
1amine in RA.
Penicillamine can affect collagen cross-linking in two major 
ways (Nimni, 1977). Since it contains both a thiol and an amino
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group it can form thiazolidines with lysyl and hydroxlysyl der­
ived aldehydes (Nimni, 1977; Siegel, 1977). The significance of 
such an effect is speculative and among the ideas proposed is a 
stabilising effect on collagen making it less susceptible to de­
gradation (Crawhall et al, 1979). The other way in which D-penicil- 
lamine can affect collagen cross-linking is by chelating the copper 
necessary for the activity of the enzyme lysyl oxidase which is 
responsible for the cross-linking (Nimni, 1977). However, the very 
high concentrations of D-penicillamine needed to do this are un­
likely to be attained in vivo (Siegel, 1977; Ruckner and Murray, 
1978). Gerber (1978) has proposed that D-penicillamine may mimic 
the action of collagenase inhibitors due to disulphide exchange 
reactions thereby regulating collagenase activity in the rheumatoid 
joint. This same author has shown that in vitro the drug inhibits 
the sulphydryl dependent heat dénaturation of IgG (Gerber, 1978) 
and so might prevent the formation of autoantigenic IgG aggregates in 
vivo . Similarly, free radical associated IgG aggregation may be 
inhibited by the scavenging of these radicals (Wickens and Dormandy, 
1984).
While these biochemical effects might explain some of the 
benefits achieved by D-penicillamine in RA, the drug appears to have 
a more profound effect on the immune response in the disease sugg­
esting an immunomodulatory mechanism of the drug. In vitro mito- 
genic-induced lymphocyte proliferation can be enhanced at low doses 
of penicillamine and inhibited at higher doses (Room et al, 1979). 
D-penicillamine has also been shown to synergise with copper ions 
in vitro to suppress lymphocyte function by inhibiting T-cell 
function (Lipsky and Ziff, 1980). This has been attributed to the 
generation of by D-penicillamine-copper complexes which suppress
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T-cell activity (Lipsky, 1984). However, no convincing demonstration 
of inhibition of T-cell activity in vivo by D-penicillamine has yet 
been shown. Evidence has been produced indicating a possible immuno- 
regulatory role for D-penicillamine in RA by affecting SH-dependent 
reactions of monocytes (McKeown et al, 1984a). The role of SH 
groups in the immune response and their significance in RA are dis­
cussed in section l.C. 
l.B.2. SIDE EFFECTS OF PENICILLAMINE
The use of penicillamine as a therapeutic agent in RA has been 
complicated by its ability to induce adverse side-effects (Andrews 
et al, 1973). These effects are unpleasant but most of them are not 
serious and are generally reversible upon cessation of treatment. Per­
haps the most common problems encountered with penicillamine therapy 
are nausea, rashes and loss of taste. There are two main types of 
rashes seen. One of them occurs early after the start of treatment 
but generally stops upon cessation of the drug and does not recur 
upon recommencement. The other rash occurs much later and is more of 
a problem although, fortunately, it occurs less commonly. As with 
rashes, loss of taste occurs in about 25% of patients. It generally 
returns whether the therapy is discontinued or not so cessation of 
treatment is unnecessary. Proteinuria is a more important complic­
ation of penicillamine therapy because it may lead to withdrawal of 
the drug. It occurs in about 15% of patients and is of variable 
severity. In some of these cases nephrotic syndrome can occur. It 
is essential to monitor renal function during treatment with penicil­
lamine. Haematological abnormalities can also occur in patients 
receiving penicillamine of which thrombocytopenia is the most 
common. When this occurs, treatment should be discontinued to fac­
ilitate recovery but can generally be cautiously restarted. Neutro­
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penia is much more serious but fortunately less common. There are 
some blood dyscrasias which continue despite cessation of treatment 
and in some of these cases deaths have occurred. Immunological ab­
normalities have been reported with penicillamine e.g. drug-induced 
systemic lupus erythematosus (SLE) but fortunately these are very 
rare.
The occurrence of side effects in RA patients treated with 
penicillamine and the variation in efficacy seen with the drug may 
be related to plasma levels of the drug (or its metabolites). How­
ever, technical difficulties in developing assays to measure the 
drug in biological fluids have led to a lack of information regard­
ing this situation. Before discussing these problems and approaches 
to assaying D-penicillamine, it is necessary first to outline the 
chemistry of the drug.
l.B.3. STRUCTURE AND CHEMISTRY OF PENICILLAMINE
Penicillamine is a tri-functional amino acid containing car­
boxyl, amino and sulphydryl groups (Fig.2). It differs from cysteine 
in that the two hydrogen atoms attached to the ^-carbon atom in 
cysteineare substituted by methyl groups so that penicillamine may 
be designated dimethyl cysteine. The asymmetrical CX-carbon atom 
means that penicillamine can exist in D- and L-stereoisomeric forms 
as a DL form if synthesised from a racemic precursor.
Early studies indicated metabolic and toxicological differences 
between the different forms of the drug (Kuchinskas et al, 1957).
Due to its lesser toxicity it is the D-form which is solely used 
for pharmacological purposes. The optical laevorotation of D-pen­
icillamine in aqueous solutions means it is properly designated D(-) 
penicillamine, although in this thesis (-) is omitted.
-35-
The main chemical reactions in which D-penicillamine can part­
icipate are characteristic of its three functional groups. The main 
reactions are listed in Table 2.
The stability of complexes with divalent ions falls in the 
following order (Kuchinskas and Rosen, 1962; Doornbos and Faber,
1964); Hg, Pb, Ni, Cn, Zn, Cd, Co, Fe, Mn. The exact nature of the 
linkages is unclear and appears to vary from metal to metal (Doornbos 
and Faber, 1964). The chelating properties of the drug have led to 
its use in Wilsons Disease and heavy metal poisoning.
In aqueous solutions, it is slowly oxidised to penicillamine 
disulphide this reaction being facilitated by the presence of air, 
light, alkaline pH, raised temperatures and traces of heavy metals 
(Kucharchyk and Shahinan, 1981). The ability of penicillamine to 
undergo disulphide formation and take part in thiol-disulphide ex­
change reactions means it can react with both cysteine and cystine 
to form the mixed disulphide, cysteine-penicillamine disulphide.
This is more soluble than cystine and its formation reduces "cystine 
stone" formation in renal tubules, this being the rationale behind 
penicillamine therapy in cystinuria (Crawhall et al, 1963). 
l.B.4. ASSAYS FOR PENICILLAMINE IN BIOLOGICAL FLUIDS
The inherent reactivity of D-penicillamine has proved to be a 
considerable problem in the development of reliable, accurate assay 
procedures. Only in recent years have procedures been adopted which 
have eliminated problems in penicillamine analysis. These have been 
mainly the use of EDTA to chelate any metal ions present, thereby 
preventing penicillamine oxidation and chelation, and manipulation 
of the pH to keep the drug in its desired form (Bergstrom et al,1980), 
Most of the more recent assays developed have been high performance 
liquid chromatographic (HPLC) methods coupled with some form of
-36-
(A) COMPLEX FORMATION.
(i) P-SH + heavy metals (Ou, Zn) (P-SH) - metal
(il) P-SH + pyridoxal thiazolidine
derivative
(B) BISULPHIDE FORMATION
(i) P-SH + thiol-SH (e.g.P-SH,cysteine) P-S-S-thiol
(ii) P-SH + protein-SH P-S-S-protein
(C) THIOL-DISULPHIDE EXCHANGE
(i) P-SH + disulphide (thiol-S-S-thiol) P—S—S—P + thiol-SH
(ii) P-SH + protein-S-S-thiol P-S-S-protein 
+ thiol SH
(D) METHYLATION





BIOCHEMICAL REACTIONS OF D-PENICILLAMINE
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electrochemical detection (Rabenstein and Saetre, 1977; Saetre and 
Rabenstein, 1978). Abounassif and Jeffries (1983) developed sample 
preparation methods together with an HPLC system utilising glassy carbon 
based electrochemical detection which allowed measurement of total drug 
in plasma. However, there are still many problems associated with this 
assay. In this project, the aim was to modify and further develop this 
basic technique to determine penicillamine concentrations in plasma and 
utilise the method to study the drug’s pharmacokinetics in normal volun­
teers and RA patients. This should allow possible correlations between 
the pharmacokinetics and metabolism of the drug and its efficacy and tox­
icity to be studied.
l.C. THE ROLE OF SH GROUPS IN RHEUMATOID ARTHRITIS 
l.C.l. THIOL CONTAINING COMPOUNDS AS ANTI-RHEUMATIC DRUGS
Many of the second-line anti-rheumatic drugs have free sulphydryl groups 
or are converted to SH-containing compounds in vivo (Hunneyball 1980).
Both penicillamine and aurothiomalate, perhaps the most widely used second- 
line agents, are thiols and it has been pointed out that all the gold salts 
used in controlled, long-term clinical studies have been thiols (Munthe e_t 
al , 1978). Levamisole, another second-line drug with anti-rheumatic act­
ions, has been shown to have similar biological and clinical effects to 
D-penicillamine and gold (Symoens and Schuermans, 1979). In vivo, the 
drug is metabolised to a number of products including DL-2-oxo-3-(2- 
mercaptoethyl-5-phenyl-imidazolidine) (OMPI) which has a free SH group 
(DeBrabander et al, 1978). It has been proposed that the effectiveness 
of these second line drugs may be due to their SH groups (Jaffe, 1980).
Such a hypothesis seems eminently reasonable in view of the disturbance 
in SH levels seen in RA.
1.0.2. SULPHYDRYL LEVELS IN RA
Depressed serum SH groups are a feature of active RA (Lorber et al.
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1964) and serial measurements show an inverse correlation with disease 
activity (Haataja, 1975). In addition, erythrocytes from RA patients 
have low SH levels which correlate with serum SH levels (Lorber and Chang, 
1968). Serum SH levels rise to normal in those patients showing good 
clinical response to D-penicillamine and aurothiomalate treatment (Dixon 
et al, 1980).
In the serum,most of the SH groups are on albumin molecules. Oxidation 
of these groups with small thiols such as cysteine to form mixed disulph­
ides is apparently the reason for the depressed SH levels observed in RA. 
(Thomas and Evans, 1975). Although albumin levels are reduced in RA and 
may be partially responsible for the depressed SH levels, lack of correl­
ation between albumin and thiol concentrations indicates it is not a major 
contribution (Banford et al, 1982). A number of reasons for the disulph­
ide formation are possible. Caeruloplasmin, an acute phase reactant, 
oxidises low molecular weight thiols to disulphides (Albergoni and Cassini, 
1978) and may play a role in albumin-cysteine disulphide formation. Rel­
ease of reactive oxygen intermediates from inflammatory phagocytic cells 
has been suggested as another mechanism to catalyse such a reaction (Hall 
et al, 1984).
l.C.3. ROLE OF SH GROUPS IN THE IMMUNE RESPONSE
Disturbed thiol expression in RA may be involved in the defective imm­
unoregulation observed in the disease which may play a role in its patho­
genesis. Several aspects of the immune response appear to involve sulph­
ydryl groups. In animal studies, simple thiols such as 2-mercaptoethanol 
(2-ME) have been shown to potentiate the immune response in vitro includ­
ing lymphocyte proliferation (Broome and Jeng, 1973; Bevan et al, 1974) 
and antibody responses (Click et al, 1972). Click et al showed that 2-ME 
affected an early event in the immune response since it was unnecessary 
to add the reagent to the cultures daily. In humans, lectin-induced
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lymphocyte proliferation in vitro can be inhibited by the addition of SH- 
blocking agents such as diamide and para-hydroxymercuri-phenylsulphonic 
acid (pHMPSA) (Chaplin and Wedner,1978). Again, these authors concluded 
that SH groups were involved in an early event since addition of the SH- 
blocking agents was required at the start of culture to have inhibitory 
effects. Several lines of evidence suggest that the important SH groups 
are present on the cell surface and are not intracellular. Diamide enters 
cells only very slowly (Chaplin and Wedner 1978) and pHMPSA does not app­
arently permeate cell membranes (Tsan and Berlin 1971). Similarly, gluta­
thione, an impermeant thiol, enhances lymphocyte proliferation in a fash­
ion akin to 2-ME whereas cysteamine phosphate, a compound which is only 
converted to a SH-containing compound intracellularly, has no such effect 
(Noelle and Lawrence,1979).
These observations suggest that in RA the oxidation of functional SH- 
groups may be involved in the observed aberrant immune response. Such 
a view is enhanced by the immunomodulatory nature of SH-containing second- 
line anti-rheumatic drugs such as aurothiomalate and penicillamine. Pre­
vious studies in this laboratory have sought to analyse the possible role 
of SH groups in immunoregulation in RA which might be relevant to the 
pathogenesis of the disease (McKeown et al, 1984a). These showed that 
peripheral blood mononuclear cells (PBMCs) obtained from RA patients treat­
ed with NSAIDs (RA-NSAID) produced significantly less IgG in response to 
PWM in vitro than normal cells. Addition of 2-ME (5 x 10”^M) to the RA- 
NSAID PBMCs stimulated IgG synthesis to normal values, a procedure which 
had no significant enhancing effect upon IgG production by PBMCs from 
healthy controls or from D-penicillamine treated patients (RA-D-pen).
When monocytes were pre-incubated with the SH-blocking agent pHMPSA and 
added back to lymphocytes in reconstitution experiments,IgG production 
was abolished showing that monocytes require free cell surface SH groups
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for their accessory function in the immune response. Further experiments 
in which monocytes were titrated back to lymphocytes demonstrated that 
monocytes from RA-NSAID patients exhibited impaired accessory cell 
function with respect to normal monocytes. This could be corrected by 
the addition of 2-ME. RA-D-penicillamine monocytes showed normal access­
ory function which, like those from normal controls, was unchanged by 2ME 
treatment. These studies strongly suggest that defective monocyte acc­
essory cell function in RA results from reversible oxidation of the cell 
surface SH groups. Support for this comes from other studies which have 
shown a significant enhancement of proliferation of PBMCs from RA pat­
ients to PHA in the presence of 2-ME (Corrigall and Panayi, 1979). De­
pressed SH levels on PBMCs probably result from the same oxidative mech­
anisms that diminish serum SH groups and erythrocyte membrane thiols in 
RA. In vitro,these can be re-exposed following chemical reduction by 2- 
ME leading to enhancement of the accessory cell function. PBMCs from 
D-penicillamine treated patients show normal IgG synthesis and monocyte 
accessory cell function and are.unresponsive to enhancement by 2-ME in 
vitro. It may be that D-penicillamine exerts its beneficial effects in 
RA by modulating SH-dependent mononuclear cell functions especially those 
of monocytes active in the immune response.
The aim of this part of the project was to delineate monocyte funct­
ions dependent on the expression of free SH groups on the cell surface 
relevant to their accessory cell function since they represent possible 






All solvents were of HPLC grade (Fisons Ltd.,
Loughborough, U.K.). The water used for aqueous mobile 
phases was deionised and doubly-distilled by means of a Fi-stream 
pre-de4o niser and water still (Fisons Ltd.)
Reagents and Solutes






Sigma Chemicals Ltd, 
Poole, U.K.
Disodium hydrogen ortho­
phosphate, sodium dodecyl 
sulphate (primar grade)




Koch Light Labs, 
Colnbrook, U.K.






Liquid chromatographs were assembled from commercially avail­
able components. Constant flow pumps were used (Consta Metric III 
pumps, L.D.C. Ltd., Stone, Staffs, U.K.) fitted with additional 
custom-made pulse dampeners to maximise a pulse-free solvent flow. 
Samples were introduced by means of a high-pressure injection valve 
fitted with a constant volume loop (50 fils or 100 /Ils) (Rheodyne 
7125, Rheodyne Ltd., Cotati, California, U.S.A.). All column 
fittings, tubing and plumbing were supplied by H.E.T.P. Ltd., 
Macclesfield, U.K.
The final column configuration is shown in the results section. 
Switching of the solvent flow in the penicillamine determination 
was achieved by means of a high-pressure switching valve (Rheodyne 
7000, Rheodyne Ltd.).
Temperature of the HPLC system was maintained at 25^ by a 
heated water bath (Type 400.010, Gallenkamp, Loughborough, Leics,
U.K.).
Mobile phases were degassed under vacuum, greater than 500 mmHg 
for 20 minutes. The degassed condition was maintained for up to 24 
hours by use of a Dupont Flotation degassing system (Jones 
Chromatography, Llanbradach, Wales, U.K.).
Detection Systems
The column eluent was monitored by passing it through the flow­
cell of an electrochemical detector (BAS LC-4A, Bio-analytical systems, 
West-Lafayette, U.S.A.) fitted with a thin-layer cell. In the final 
system for penicillamine determination the cell contained a gold- 
mercury electrode (BAS, TL-6A). The initial HPLC system utilised 
a glassy carbon electrode (TL-4A). The reference electrode in all
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cases was an Ag/AgCl electrode (RE -1).
Recorder
The detector output was recorded on a potentiometric chart 
recorder (JJ CR650S recorder, J.J. Ltd., Southampton, U.K.).
The recorder voltage was changed in accordance with the voltage 
of the detector employed.
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2.A.3. METHODS
HPLC grade solvents and doubly distilled, de-ionised 
water were used to make up the mobile phases to minimise contam­
ination. Mobile phases were freshly prepared to avoid concent­
ration changes and filtered using 0.45 jwn filters (Type HA, 
Micropore filters, Millipore Ltd., Harrow, Middlesex, U.K.)
Mobile phase pH was checked usinga Howe 6031 pH meter, V.A.Howe 
Ltd., London, SW18, U.K.).
Mobile phases were passivated by degassing under a vacuum 
exceeding 500 mmHg for 20 minutes. Timing of the degassing was 
precise to minimise any organic solvent loss. The degassed con­
dition was maintained by a Du-Pont flotation degassing system 
which is effective for at least 24 hours.
Procedures- for the determination of penicillamine 
Calibrations
A stock solution of D-penicillamine in mobile phase con­
taining lgL~^ EDTA was used to prepare dilutions in the range 
1 X 10"^M (0.1492 /xgml"^) to 1 x 10"^M (149.2 /igml"^). An 
identical calibration was performed for D-penicillamine spiked 
into plasma, the required amount of D-penicillamine in mobile 
phase being added in 0.01 ml aliquots to 0.99 mis of plasma.
The spiked plasma samples were then treated according to the method 
for total drug in clinical plasma samples as described below.
Total D-Penicillamine in plasma 
Clinical plasma samples and spiked plasma samples (both 1ml) 
were pipetted into glass flow tubes to which 0.36 mis of dithio­
threitol (10 mgml  ̂ ) was added, followed by 1.64 mis of di­
sodium hydrogen phosphate buffer (0.05M) to give a final volume of 
3 mis. After thorough mixing of the contents the tubes were incub-
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ated at 60°C for 3 hours in a water bath. Upon completion of the 
incubation period, the contents were again thoroughly whirlimixed 
and samples spun at 4500 r.p.m. for 25 minutes in a Hettich Uni­
versal Centrifuge (Arthur Horwell Ltd., London, U.K.). The super­
natants were removed and pipetted into Eppendorf microfuge tubes 
(Sterilin Ltd., Felthara, Middlesex, U.K.) which were then spun in 
an Eppendorf microfuge for 1 minute at maximum speed to further re­
move any debris. The supernatants were then filtered through Amicon 
micro-filters (0.2 fim pore size) (Amicon, Woking, Surrey, U.K.).
The filtrates (400 fJtXs) was then added to 100 pis of mobile phase 
containing IgL ^ EDTA in small sample tubes (TSP ^  , Fison's Ltd.,
Loughborough, U.K.). 50 jUls of the samples were injected onto a
15 cm. pre-column containing Spherisorb-NH^ (5 /X̂ i) by means of the 
injection valve. At 85 minutes precisely, the running samples were 
transferred to the main analytical 5 cm Spherisorb-NH^ column by 
means of the switching valve. After elution of the penicillamine 
peak the flow was switched back using this valve so that the next 
sample could be introduced onto the pre-column. In this way, "over­
lapping" of samples was achieved thereby reducing the effective analy­
sis time. All samples were injected in duplicate.
Concentrations of unknown clinical samples were determined 
by use of an external standard method. Spiked plasma samples contain­
ing a known drug concentration were treated in the same way as clin­
ical samples and their filtrates were injected before and after dup­
licate clinical samples. The mean peak height of these known stand­
ards was taken to be the peak height relating to that particular con­
centration. The concentration of the unknown clinical sample was 
then calculated by the following equation:-
peak height (unknown) ^  concentration of known standard 
peak height(known standard
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This system was employed due to the lack of an internal standard 
and also to compensate for any changes in detector sensitivity 
throughout the analysis.
2.A.4. HUMAN STUDIES 
Volunteers
Five healthy volunteers, 3 males and 2 females (age range 22 
to 42 years) were each given an oral dose of 500 mg. D-penicillamine 
on 2 separate occasions. The first of these was following an overnight 
fast with no food or milk allowing for two hours after dosing. On 
the second occasion the drug was taken in the middle of a light break­
fast. On each occasion blôod samples were obtained by venepuncture 
at 1, 2, 3, 4, 6, 8 and 24 hours post-dosing (approximately) and placed 
in EDTA tubes. The plasma obtained by centrifugation was then assayed 
for total drug as described previously. Area under the curve (AUG) 
values were calculated using the trapezoidal rule.
Statistical analysis was performed using the Wilcoxon’s rank 
sum test.
Patients
Patients with active RA were admitted to the Royal National Hos­
pital for Rheumatic Diseases, Bath, to commence penicillamine therapy. 
Clinical assessment of the disease state was performed by consultant 
rheumatologists at the hospital as was the assessment of their suitabil­
ity to undertake such therapy. Treatment was dictated by the physicians 
and not influenced in any way by the study for which full clinical app­
roval was obtained. The patients gave their consent for the study to 
be undertaken. Their previous case histories were taken as were notes 
of any drugs being administered or which had been previously administ­
ered.
After an overnight fast, patients were given 125 mg. penicilla-
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mine by mouth next morning without food. Blood samples were with­
drawn by venepuncture at regular intervals (or as necessitated by 
hospital routine) and the plasma obtained for determination of drug 
concentrations.
Wherever possible, patients returned to out patient clinics 
after an initial stay in hospital and samples were obtained at such 
clinics in order to follow up the concentration of the drug to steady 
state levels.





All reagents and disposable 
tissue culture plastics, 
except where otherwise 
stated;
Supplier
GIBCO Bio-cult Limited, 
Paisley, Scotland.
All chemicals,except where 
otherwise stated (including 
radiochemicals):




Pharmacia (GB) Limited, 
Milton Keynes.
Leukotriene B, Miles Laboratories Limited, 
Slough, Berkshire.
Scintillation grade toluene; British Drug Houses Limited, 
Poole.
Scintillation fluid (Liqui- 
sc int) :
National Diagnostics Limited 
N.J. USA.
Scintillation vials: Richardsons of Leicester, 
Leicester.
Lab-Tek tissue culture: 
chamber/slides (Type 4808)





MSE Chilspin 2 centrifuge, 
MSE Mistral centrifuge:
Supplier




Flow Laboratories Limited 
Irvine, Scotland.
E. Leitz (Instruments) Limited, 
Luton.
Dynatech





United Technologies, Packard, 
Berkshire.
Perkin-Elmer MPF 44A 
Fluorimeter:
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2.B.3. ROUTINE BUFFERS AND MEDIA
Phosphate buffered saline (PBS) x 10
T -4. - 1gLitre
Sodium chloride 80.000
Potassium chloride 2.000
Disodium hydrogen phosphate 11.500
Potassium dihydrogen phosphate 2.00
The above constituents were dissolved in 1 litre distilled water 
and the pH adjusted to 7.3 by use of 3M NaOH. The buffer was 
then filter sterilised (Millipore filter, 0.22 /t'npore size) 
and stored at 4°C.
In some cases, the buffer was diluted 10-fold before use to 
give 1 X buffer and the pH again corrected to 7.3.
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Potassium dihydrogen phosphate (anhydrous) 0.060
Disodium hydrogen phosphate (anhydrous) 0.048
The above constituents were dissolved in IL of distilled water 
and the pH adjusted to 7.3. The solution was then filter 
sterilised (Millipore filter, 0.22 /irn pore size) and stored 
at 4°C until use.
Cell Culture medium RPMI 1640
volume (mis) 
RPMI 1640 (lOx strength) 100
7.5% sodium bicarbonate solution 27
Penicillin and Streptomycin solution 
(5000 Unitsml”^) 20
200 mM glutamine 20
The above were mixed and the total volume made up to IL using
sterile distilled water. The pH was corrected to 7.3 using
sterile 3M NaOH.
Where appropriate, 10% foetal calf serum (FCS) was added re­
placing 100 mis of the distilled water.
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Hank's Balanced Salt Solution (HBSS) + 15% FCS
volume (mis
H.B.S.S. (10 X  strength) 100
7.5% sodium bicarbonate solution 27
Penicillin and streptomycin 
solution (5000 Unitsml”^) 20
Foetal calf serum 150
The above were mixed and the total volume was made up to IL 
using sterile distilled water. The pH was adjusted to 7.3 
using sterile 3MNaOH, the solution was then filtered and 
stored at 4°C.
Ca^^ ion assay simplified medium
The following were added to 1 x PBS (1 litre)
Calcium chloride 1 mM
Glucose 5 mM
PRS buffer
The following were added to 100 mis. of distilled water
Sodium chloride 1.0226 g
Potassium dihydrogen phosphate 0.1701 g
Glucose 0.1238 g
32 mis of this buffer was added to 4 mis Horse-Radish peroxidase 
(Type II) (0.0123 g/100 mis. distilled water) and 4 mis phenol 
red (2gL  ̂ distilled water). The pH was adjusted to 7.3 by 





Sodium carbonate 1.59 g
Sodium hydrogen carbonate 2.93 g
Sodium azide 0.2 g
The above constituents were dissolved in sterile distilled 
water and the pH adjusted to 9.6. The buffer was stored at 
room temperature for not more than two weeks.
PBS/Tween
Tween 20 (Polyoxyethylene sorbitan 
monolaurate) 0.5 ml
Sodium azide 0.2 g
The above constituents were added to IL PBS and the buffer
stored at room temperature.
Diethanolamine
Diethanolamine 97 mis
Distilled water 800 mis
Sodium azide 0.2 g
Magnesium Chloride hexahydrate 0.1 g
This solution was then adjusted to pH 9.8 with IMHCl. The 
total volume was made up to IL with distilled water and the




0.5 g of BSA { > 9 9 %  globulin free) were added
to 100 mis of 1 X PBS buffer.
Scintillation Fluid
To 2.5 litres of toluene was added
2.5 - Diphenyloxazole (PPD) 12.50 g




Peripheral blood mononuclear cells (PBMCs) were prepared from 
heparinised blood by density centrifugation on FicoUPaque (Boyum 
1968). Blood was diluted 1:1 with CMFSS and 7 mis. layered onto 3 
mis. of Ficoll-Paque in sterile, polystyrene tubes which were then 
centrifuged at 400 g. for 30 Tins., at 18°C. The PBMCs were removed 
from the interface, washed three times with CMFSS and resuspended in 
1 ml. RPMI 1640. The cells were counted in a haemocytometer and the 
concentration adjusted to 1 x 10^ cells per ml.
In some experiments, these cells were separated into monocyte 
and lymphocyte-enriched populations by centrifugation through 52%*(^) 
Percoll. PBMCs in 1 ml. RPMI 1640 were carefully layered onto 2 mis. 
of Percoll in sterile, polycarbonate tubes which were centrifuged at 
750 g for 30 mins. at 18°C. Monocytes were obtained from the supported 
band and lymphocytes from the pellet. Lymphocytes were then further 
depleted of contaminating monocytes by passage through a 10 ml. Sepha­
dex G-10 column equilibrated with HBSS + 15% FCS. Cells were allowed 
to remain bn the column for 5 minutes before elution with HBSS + 15% 
FCS. Purity of the cell populations was assessed by non-specific 
esterase staining which showed the monocyte population to be >  80% 
pure and monocyte contamination of the lymphocytes to be <  1%. All 
tissue culture experiments were performed using aseptic technique.
2.B.5. CELL CULTURE AND ASSAYS 
Lymphocyte Proliferation 
PBMCs (1 X 10^ ml ^ ) were cultured in 0.2 ml aliquots of RPMI 
1640 containing 10%' FCS in round bottomed microtitre plates. Cultures 
were set up in the presence or absence of PHA (1 />tgml”^) and incubated 
for 72 hours at 37°C in a humid atmosphere of 5% CO^ in air. Cells 
were pulsed with 0.5 pC± ^[H]- thymidine (sp. 5Ci mmol”^) 4 hours
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before termination of the culture incubation. The cells were harvest­
ed onto glass fibre filter discs and dried. These were placed into 
vials containing 2 mis scintillation fluid and the uptake of radio­
isotope determined by liquid scintillation spectrometry.
IgG production
PBMCs, lymphocytes and monocytes were cultured alone or in var­
ious combinations. PBMC (1 x 10^ cells ml ^^ were cultured in 1 ml. 
aliquots of RPMI 1640 + 10% FCS in large-well flat-bottomed culture
plates. Incubations were set up in the absence or presence of PWM
1
(final dilution 200). Cultures were incubated for 7 days (except 
where stated) at 37^C in a humid atmosphere of 5% CO^ in air. The 
supernatants were harvested and assayed for IgG content by enzyme- 
linked immunosorbent assay (ELISA).
In reconstitution experiments, 50 p,ls monocytes (1 x 10^ cells 
ml ^ ) were added to 950 pis of lymphocytes (1 x 10^ cells ml ^ ) and 
controls performed in the absence of monocytes.
Enzyme-linked immunosorbent assay (ELISA) for IgG
100 pXs of an optimal dilution of a goat anti-human polyvalent 
immunoglobulin were dispensed in each well of a flat-bottomed micro- 
ELISA plate. The plates were covered and incubated for Ihr at 37°C 
under humid conditions. The plates were used immediately or stored at 
4°C until needed. They were washed three times with coating buffer, 
dried thoroughly and 100 pis of PBS/BSA added to each well. After 
incubation for 30 minutes at 37^C in humid conditions 100 pis of each 
doubling dilution of the test supernàbants were added to the appropriate 
wells. Standard IgG containing solutions (100 pis ) were also added 
and doubly diluted to construct a standard curve. Following incubat­
ion for 1 hr at 37°C in humid conditions, the wells were washed thor­
oughly with PBS/Tween and dried. 100 pis of an alkaline phosphatase
-57-
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conjugated anti-human IgG^(100 dilution) were then added to each well 
and the plates incubated for 1 hr at 37°C in humid conditions before 
extensive washing witd PBS Tween and thorough drying. 100 pis of 
alkaline phosphatase ;substrate (p-nitrophenyl phosphate) in diethan­
olamine buffer (1 mg ml ^ ) were then added to each well and the colour 
allowed to develop at room temperature. Once the maximum known IgG 
concentration well had reached an absorbance reading of 1.0 at 405 nM, 
the plates were read at this wavelength in a Dynatech micro-ELISA 
reader. IgG concentrations of unknown supernatants were determined 
by reference to the standard IgG calibration curve simultaneously con­
structed.
Blockade of cell membrane SH groups
Cell surface SH groups were blocked by pre-incubating cells for 
1 hr at 37°C with an irreversible non-penetrating SH-blocking agent, 
p-hydroxymercuriphenyl sulphonic acid (pHMPSA) (Tsan and Berlin, 1971). 
The cells were then washed three times with CMFSS and resuspended in 
RPMI 1640.
Monocyte-lymphocyte clustering
Monocytes and lymphocytes were obtained as previously outlined. 
Both populations were incubated in absence (unblocked) or presence of 
5 X 10 ^M pHMPSA (blocked) for 1 hr at 37°C. Monocytes (unblocked 
and blocked) were then diluted in RPMI 1640 + 10% FCS to 400,000 cells 
per ml. and 0.4 mis of these cell solutions added to appropriate com­
partments in Lab-Tek tissue culture chamber/slides (type 4808) which 
were incubated for 1 hr at 37°C in 5% CO^ in air under humidified 
conditions. At the end of the incubation, non-adherent cells were 
flushed away by washing three times with RPMI 1640 + 10% FCS. 0.4 ml. 
aliquots of lymphocytes (4 x 10^ cells ml”^) were added to appropriate 
chambers in cross-over reconstitution experiments (i.e. blocked mono-
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cytes with blocked lymphocytes, blocked monocytes with unblocked
lymphocytes etc.). Cultures were then incubated in the absence and 
J.__
presence of 200th dilution of PWM and in some cases, purified protein 
derivative of tuberculin (PPD) (100 /tgml”^ final concentrations) for 
16 hr at 37°C in 5% CO^ in air under humidified conditions. At the 
end of the incubation period, the cells were fixed by the addition of 
1% glutaraldehyde in O.IM Cacodylate buffer (pH 6.8 ) for 30 mins at 
37°C. The slides obtained were then stained using a Difquick differ­
ential stain and the number of monocyte-lymphocyte clusters counted 
under light microscopy.
Measurement of intracellular Caf^ concentrations
PBMCs were prepared as previously outlined and the concentration
7 —1 2+adjusted to 2 x 10 cells ml” . The fluorescent quinoline Ca ind­
icator, Quin-2 (TsLen et al, 1982 a,b) was added in its ester form 
(Quin-2/AM) at a final concentration of 20 /IM and incubated with the 
cells for 20 minutes at 37°C. At the end of this period, the cells 
were diluted 10-fold with RPMI 1640 and the incubation at 37°C con­
tinued for another 40 minutes to complete Quin-2 loading. The cells 
were then incubated with 5 x 10”^M pHMPSA or CMFSS (in controls) for
1 hr at 37°C and resuspended at a concentration of 1 x 10^ cells per 
ml. in RPMI 1640. After being spun in a microfuge (low-speed), the 
cell pellets were resuspended in 2 mis simplified medium and the sus­
pensions rapidly transferred to quartz micro-cuvettes. The background 
fluorescence due to basal intracellular Ca^^ ions was monitored in a 
fluorimeter (Perkin-Elmer MPF 44A) (excitation 339 nM, emission 492nM) 
to achieve a stable baseline before 1 / t g . m l P  HA was added and the
subsequent increase in fluorescence monitored.
Measurement of ^[H]-oleic acid uptake into mononuclear cells
PBMCs were incubated with 9,10 (n) ^H] oleic acid (sp.act
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4.8 Curies/mmol) at a concentration of 4 jLtCi ml”  ̂ for 1 hour at 
37^C. Following this the cells were washed three times with RPMI 
+ 0.5% fatty acid free BSA, counted and the concentration adjusted 
to 5 X 10^ cells per ml. 1 ml. aliquots of cell suspensions were 
added to 2 mis scintillation fluid (Liqui-scint, National Diagnostics, 
N.J. USA). The ^(H )oleic acid incorporated into the cells was
then determined by measuring the radiolabel incorporated using a 
scintillation counter.
In some experiments, no washing of the cells was performed after 
the incubation step and the cells were counted, adjusted to 5 x 10^ 
cells per ml. and aliquoted into Liqui-scint.
Hydrogen Peroxide Assay
This assay is based on that developed by Pick and Keisari
(1981 ). It is based on the hydrogen peroxide-dep­
endent horse-radish peroxidase-mediated oxidation of phenol-red which 
results in the formation of a compound which has an increased absorb­
ance at 610 nM at alkaline pH compared to native phenol-red 
(Figure 3 ).
Standardisation of Assay
The assay was standardisedby using hydrogen peroxide solutions 
in . CMFSS . of known concentrations. Appropriate hydrogen per­
oxide dilutions in 100 pi. aliquots were added to 100 pis of PRS- 
buffer in the wells of a flat-bottomed micro-titre plate to give hydro­
gen peroxide concentrations in the range 1 p M  to 100 pM. The plates 
were incubated at 37°C for 5 minutes and 10 pis of 3MNaOH added to 
each well to bring the pH to 12.5. The absorbance at 610 nM was 
read in a micro-ELISA reader against blanks containing 100 pis PRS- 
buffer, 10 pis 3MNaOH and 100/Us H^Og (added after the 3MNaOH). The 
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hydrogen peroxide concentration pM.
FIG. 3. Curve to standardise the micro-assay,
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the range 1 and 50 flM (Figure 3 ).
Hydrogen Peroxide production by monocytes
100 /ils aliquots of monocytes (2 x 10^ cells ml ^ ) were added 
to the wells of a flat-bottomed microtitre plate containing 100 /ils 
of PRS-buffer with HRPO together with 5 x 10"^M FMLP where approp­
riate. Wells without stimulus (FMLP), wells plus catalase (1500 Uml”^) 
and wells with stimulus plus catalase served as controls. Each det­
ermination was performed in triplicate. The plates were incubated 
at 37^0 for 30 minutes and the reaction stopped and pH adjusted to
12.5 by the addition of 10 /ils 3MNaOH. The absorbance was then read 
immediately in a micro-ELISA reader. H^O^ production by the cells 
was calculated by reference to the standard curve constructed using 
known H^O^ concentrations.
Superoxide production by monocytes
100 /ils aliquots of monocytes (2 x 10^ cells ml”^) were added 
to the wells of a flat-bottomed microtitre plate containing 100 /ils 
of a phenol-red free balanced salt solution with 160 fiM ferri-cytochrome 
c together with 50 /ig heat-aggregated IgG (HAGG) where appropriate.
Wells without stimulus (HAGG) and stimulus plus superoxide dismutase 
(SOD) (300 U ml ^ ) served as controls. Each determination was per­
formed in triplicate. The plates were incubated for 1 hr at 37°C 
and the absorbances read in a micro-ELISA reader at 550 nM against 
a blank containing no cells. Results were expressed in terms of n moles 
cytochrome C reduced using the formula 
A = E e l  where A = absorbance
c = concentration (mM)
1 = length of light path (cm)
-1 -1E = Extinction coefficient = 21 mM cm
—62—
The length of light path (1) was determined by measuring the 
radius (r) of the wells and then applying the formula:
Volume = r^h
where h is the height of liquid in the well and therefore the length 





3.A. DEVELOPMENT OF A MODIFIED HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
SYSTEM FOR THE DETERMINATION OF PENICILLAMINE.
The inherent reactivity of D-penicillamine has caused considerable 
problems in the development of reliable, accurate assay procedures. A 
number of pharmacokinetic studies measuring free D-penicillamine in bio­
logical fluids,mostly by HPLC coupled with mercury based electrochemical 
detection,have been performed but no studies have been performed measur­
ing total D-penicillamine except for that carried out by Muijsers ^  
al (1979) using an amino-acid analyser. This method is limited, however, 
by the long analysis times involved. Table 3 shows a list of published 
pharmacokinetic studies. In 1983, Abounassif and Jefferies developed 
sample preparation procedures coupled with a HPLC system to detect total 
D-penicillamine in human plasma. However, a number of problems assoc­
iated with the system made routine analysis difficult. The initial aim 
of this study was to develop and modify this system to eliminate these 
problems rendering it suitable for routine analysis.
By initially treating plasma samples with the reducing agent Di- 
thiothreitol (Cleland’s Reagent) (Cleland, 1963), Abounassif and Jeffer­
ies reduced the oxidised, disulphide forms of penicillamine to the red­
uced SH-form of the drug and measured total drug in this form by their 
HPLC system. The chromatographic conditions employed by these workers 
are shown in Table 4 . One of the major difficulties of the system
was the high detector voltage employed to detect D-penicillamine (1.2V). 
At high voltages ( l.OV) there is a high background current and con­
sequently high background noise which caused problems in detecting the 
D-penicillamine peak at low concentrations of the drug where high det­
ector sensitivity was needed. A voltamagram was constructed whereby a * 
fixed concentration of drug in mobile phase was injected onto the column 
and the voltage i.e. the potential difference (p.d.) between the elect-
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Study
Saetre and Rabenstein 197 8 Total PSH in non-protein 
fraction, free PSH
Muijsers et al 1979 Total PSH
Bergstrom et al 1981 Free PSH
Wiesner et al 1981 Free PSH
Butler et al 1982 Free PSH
Kukovetz et al 1983 Free PSH
Schuna et al 1983 Free PSH
Brooks et al 1984 Free PSH
Key PSH = penicillamine
TABLE 3. Previous studies of D-penicillaminepharmacokinetics.
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PARAMETER ASSAY CONDITIONS
Mobile phase 5% methanol (^),0.1gL"^EDTA, 
and 5 x ICT^ sodium dodecyl 
sulphate in 0.05M citrate 
phosphate buffer
Stationary phase Spherisorb NH^ 5jLtm 25 cm
Temperature 25°C
Flow-rate 2 ml min~^
Injection volume 100 111.
Applied potential + 1.2V vs. Ag/AgCl
Chromatography time 20 minutes
Type of electrode TL4A Glassy carbon
TABLE 4 . Initial Chromatographic conditions for analysis of 
total and free penicillamine in plasma
-66-
rodes of the electrochemical detector altered. This was to ascertain 
the voltage needed to give a maximum response to D-penicillamine to 
find if it was possible to reduce the detector voltage employed but 
still retain the ability to detect D-penicillamine maximally. The 
voltamagram is shown in fig.4. There was only a minimal response 
to D-penicillamine at low voltages below +0.9V i.e. the potential diff­
erence was insufficient to cause significant ionisation of the D-pen­
icillamine molecule (possibly carboxy-and/or amino-groups). Between 
0.95V and 1.15V there was a sharp increase in the response which con­
tinued to increase beyond 1.2V although there was some decrease in the 
rate of response at this point. These results demonstrate the need for 
a high p.d. to detect using the glassy carbon electrode.
Similar experiments were performed to find the effect of increas­
ing the potential upon the background current and peak to peak noise. 
These results are shown in Figs. 5 and 6. The background current and 
noise remain low at potentials below l.OV. After this, vast increases 
were observed in both parameters in response to relatively small in­
creases in the p.d.
The results of all these experiments showed that a high detector 
voltage was necessary to detect D-penicillamine maximally but at such 
voltages high background currents and noise were encountered. The only 
possible solution to the problem was to use another electrode which 
would detect D-penicillamine at lower voltages. (This was eventually 
done - see later).
Fig.7 shows a chromatogram from the initial system. As can be 
seen there was a considerable number of endogenous "plasma" peaks which 
eluted prior to the penicillamine and Internal standard peaks. At low 
D-penicillamine concentrations it was necessary to increase the sensi­
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FIG. 5 . Effect of increasing applied potential upon 
the background current of the detector.
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FIG.6. Effect of increasing applied potential upon noise, 



















FIG.7. Original chromatograms from the one-column system.
The D-penicillamine peak (*D-P) elutes after the "plasma" 
peaks at about 13 minutes. The internal standard peak 
(IS) elutes at about 20 minutes. The D-penicillamine peaks 
correspond to (a) 1 x 10 (14.92 /Xgnl  ̂ ) and (b)
4 X 10~^M (5.97 Inj \ represents point of
injection.
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effect of increasing proportionately the size of the "plasma" peaks. 
Sometimes this led to these peaks partially masking the penicillamine 
peak making the determinations of low concentrations very difficult. 
These plasma peaks also caused another problem. In order to maintain 
the sensitivity of the electrode it had to be cleaned and polished at 
frequent intervals, again, interfering with use of the system on a rout­
ine basis. It was thought these plasma compounds that were being det­
ected might be contributing to the electrode’s loss of sensitivity by 
"coating" the electrode surface. In order to eliminate or, at least, 
minimise this problem and generally clean up the chromatography, a 
two-column system was devised.
As the majority of interfering peaks eluted prior to D-penicill­
amine, a two-column system linked by a switching valve was devised to 
divert these unwanted compounds away from the detector but allow D- 
penicillamine to pass to the detector. The sample was initially in­
jected onto a pre-column whose outlet flushed to waste. Just prior to 
the elution of D-penicillamine from this column the flow of the eluate 
was diverted by a switching valve to another column (analytical column) 
whose outlet directly connected to the detector. In this way, unwanted 
compounds which eluted early were flushed to waste whilst D-penicilla­
mine was passed to the detector for analysis. To reduce the analysis 
time and to avoid problems with band spreading giving poor peak reso­
lution, smaller columns were tried in the system and investigations 
showed that a 15 cm. pre-column (flow rate 1.45 ml/min) and an analyt­
ical column (flow rate 1.35 mls/min) gave good peak resolutions and 
separation with an elution time for D-penicillamine only 30 seconds 
later than the initial one-column system. The final column arrange­
ment is shown in Fig. 8
Such a configuration also meant that immediately after elution
-72-
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FIC.8. Column arrangement and port positions for switching 
system.
(i) Loading pre-column and flushing to waste
(ii) Transfer from pre-column to analytical column
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of D-penicillamine from the analytical column the flow could be reverted 
back to the initial pattern and the next sample loaded onto the pre-col­
umn. So, samples were overlapped and the effective analysis time reduced.
This two-column method initially used the glassy-carbon electrode 
of' the original method. This meant that whilst the problems of cleaner 
chromatography and maintained sensitivity were solved, the problems with the 
high applied potential persisted. This was overcome when a mercury- 
gold amalgamated electrode became available and utilised in the system. 
This electrode is specific for thiols, chelons and halideions and can 
be used at very low voltages ( +0.2V) so eliminating background current 
and noise problems. Its detection of thiols relies on the reaction of 
the mercury with the sulphydryl group. The electrode was compatible 
for the analysis of total penicillamine in plasma since the total (Oxi­
dised) drug is reduced to the free, reduced form by di-thiothreitol 
(DTT) prior to analysis and measured in this form. However, this red­
uction step posed a potential problem since di-thiothreitol is used in 
excess in this reaction to ensure completion of the reduction. Di- 
thiothreitol possesse s two free SH groups and so is capable of detection 
by the amalgamated gold electrode and since it is in excess could have 
given a large signal. The elution of DTT was found to occur at 3 min­
utes from the pre-column but the signal large enough to continue until 
very close to the switching time of 8 minutes. For this reason, the 
methanol content of the mobile phase was reduced from 5% to 4% (ç) 
which lengthened the elution time of D-penicillamine from 8*30" to 
9*15" without affecting DTT elution. This allowed the switching time 
to be delayed to 8 ’30" thus avoiding any possibility of DTT passing to 
the analytical column. So, the DTT was flushed to waste from the pre­
column.
The calibration for penicillamine spiked into plasma was linear
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over the range from 1 x 10 (0.149 /igml”^) to 1 x 10”^M (14.92 ^gml”^
having the following values : slope (3.034) and intercept (0.045). When
compared with a similar calibration in mobile phase, slope (4.015) and 
intercept (0.019), this represents a 75.6% recovery of penicillamine. 
This yield was found to be constant and stable. Both the calibrations 
were linear with r values >0.995 and are shown in Fig. 9 . The sys­
tem was found to be able to measure < 2 . 5  ng on-column whilst the co­
efficient of variation for spiked plasma samples (0.149 /ig/ml and 
5.968 ptg/ml) was less than 2% throughout the day.
An applied potential of 0.15V was employed as a voltamagram (data 
not shown) showed this voltage to give a maximal response to D-penicil­
lamine although only small differences were observed between 0.05V and
0.15V. The final conditions employed in the system are shown in Table 
5 . Chromatograms from the system are shown in Figs. 10 ,. and
11 . The actual clinical sample chromatogram (Fig. 11 .) when com­
pared with one from the original system (Fig. 7 .) shows the improve­









FIG.9 . Calibrations for D-penicillamine in mobile phase (cl)
and plasma (c2). The r values in each case exceeded 
0.995.
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PARAMETER ASSAY CONDITIONS REQUIRED
Mobile phase;
Stationary phases











4%(^) methanol. 0.1 gL"^ EDTA 
and 5 x 10”^M sodium dodecyl 
sulphate in 0.05M citrate- 
phosphate buffer, pH3.2
Spherisorb-NH^, 5/xni , 5cm 
Spherisorb-NH^, 5/in, 15cm 
35°C
1.35 mlmm  ̂
1.45 mlmin”^
100 /ils.





T a b l e 5. Chromatographic conditions for the analysis of total
penicillamine in mobile phase and plasma
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FIG.10. Chromatograms for D-Denicillamine in mobile phase;
51 indicates time for switching to analytical column;
52 indicates switching time to revert to original flow 
pattern. Chromatograms (a) and (b) show peaks for D- 
penicillamine corresponding to 0.6 /xgml  ̂ (20 nA sensi­
tivity and (c) and (d) show peaks for D-penicillamine 
corresponding to 1 /xgml  ̂ (50 nA sensitivity). Inj t 
shows point of injection.
-78-
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FIG.11. Authentic chromatogram for clinical sample :
SI indicates time for switching to analytical 
column; S2 indicates switching time to revert to 
original flow pattern. Chromatograms (a) and (d) 
are spiked standard samples for calibration purposes 
corresponding to 10 /xglml D-penicillamine. Chromato­
grams (b) and (c) are duplicate samples for an actual 
clinical sample corresponding to 6.55 fig/ml. Inj t 
shows points of injection.
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3.a  EFFECT OF FOOD UPON THE ABSORPTION OF PENICILLAMINE IN NORMAL 
VOLUNTEERS
The bioavailability of many drugs including some of the peni­
cillins is reduced when they are administered with food (Welling,
1980). Since D-penicillamine binds extensively to proteins and che­
lates metal ions, an investigation was performed to see if its bio­
availability was similarly affected.
The protocol of the study is detailed in the methods section 
and the pooled data are shown in Table 6. (Whole data are displayed 
in Appendix 1). Figures 12 and 13 show pharmacokinetic profiles (- 
food) for two of the subjects.
D-penicillamine was rapidly absorbed from the gastro-intenstinal 
tract with peak plasma concentrations observed at about 2 hours post- 
dosing. In the fasting state, the peak concentration was 8.04 - 0.34 
^Igml ^ (mean - l.s.d.) which was significantly greater than that
in the non-fasting state which was 5.54 - 0.43 ^gml”  ̂ (Wilcoxon's 
rank Sum test, significant at 1% level). The decline in the plasma 
drug concentration was biphasic in each individual with an initial 
half-life of 5.19 - 0.58 hours (mean - l.s.d.) followed by a much slow­
er decline ( T-phase half-life) of 59.43 - 9.06 hours. The half- 
life values in both fasting and non-fasting states did not differ sig­
nificantly (see Table 6). It is important to note that the values for 
the final half-life can be criticised since they were calculated over 
a time period actually less than the t? value. The area-under-the- 
cruve (AUG) value ( 0 - 2 4  hours), as calculated using the trapezoidal 
rule, in the fasting state was significantly higher than that in the 
non-fasting condition (Wilcoxon's rank Sum test, 1% level). These 
results indicate that absorption of penicillamine is significantly 









8.04 - 0.34 5.36 - 0.43 *
Area-under-the- 
curve




5.01 - 1.15 5.37 - 0.42 




56.09 -12.53 62.76 -14.39
mean 59.43 - 9.06 hours
TABLE 5 . Effect of food upon the absorption of D-penicillamine 
(figures represent mean - l.s.d. n = 5).




FIG.12 . Pharmacokinetic profile of normal subject after 
receiving 500 mg. D-penicillamine by mouth with 
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FIG.13. Pharmacokinetic profile of normal subject after 
receiving 500 mg. D-penicillamine by mouth with 
food ( o ) and without food { ■ ).
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3.C. PHARMACOKINETICS OF PENICILLAMINE IN RHEUMATOID ARTHRITIS 
PATIENTS
The total penicillamine levels in the plasma of 16 RA patients 
were determined in the first 24 hours after being challenged with 125 
mg. drug (by mouth) for the first time following an overnight fast. 
Pooled data are shown in Table 7 (Whole data are displayed in Appendix 
2).
Peak plasma concentrations were observed at about 2 hours after 
dosing. The mean plasma concentration was 2.32 - 0.79 />tgml”  ̂ (mean -
l.s.d.) - this was calculated for 14 patients where sufficient samples 
were obtained. The decline in plasma concentration was biphasic with 
an initial phase of 6.82 - 0.74 h (mean - l.s.d.) followed by a longer 
half-life of 56.22 - 3.79 h. The T-phase half-life can be criticised 
for the reason expounded previously in the study with normal volunteers. 
The half-life values are not significantly different from those obtained 
in that previous study. The area-under-the-curve for the 24 hour period 
was 45.70 - 6.56 ^gh ^ml”  ̂ (mean - l.s.d.).
The dose administered in RA patients (125 mg.) was a quarter of 
that given to normal volunteers. The mean peak plasma concentrations 
and AUC (0 - 24h) values (for the fasting condition in volunteers) did 
not show proportionality but elimination kinetics in each case were 
similar. Pharmacokinetic profiles for four of the RA patients are 





-1 -1 ( 0 - 2 4  hours; ptgh ml
Plasma elimination half-life








TABLE 7 .Pharmacokinetics of a single dose of D-penicillamine 
(125 mg. by mouth) in rheumatoid arthritis patients
(values = mean - l.s.d.)
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FIG,14. Pharmacokinetic profiles of two RA patients after 
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FIG.15. Pharmacokinetic profiles of two RA patients after 




A.A. EXPERIMENTS TO FIND A REVERSIBLE SH BLOCKING AGENT
The defective accessory function displayed by monocytes in 
vitro is due, at least partially, to oxidation of cell surface SH 
groups (McKeown et al, 1984a). The aim of this part of the project 
was to investigate the SH dependence of monocyte functions relevant 
to their accessory function in the immune response.
Initial experiments were performed to find a SH-blocking agent 
whose inhibitory effect upon the immune response in vitro could be 
reversed by the action of 2-ME so providing a model system akin to 
that seen with RA cells in which to study monocyte SH dependence. 
Early investigations examined the effect of various SH blocking/oxi­
dising agents upon mitogen-stimulated mononuclear cell proliferation 
and the ability of 2-ME to reverse any inhibitory effect. PHA was 
used at a concentration of 1 /xgml ^ , shown to be the optimum by pre­
liminary experiments, whilst PWM was used at a number of different 
dilutions. Figure 16 shows the effect of DTNB (Ellmans Reagent,
5,5’-dithiobis (2-nitro benzoic acid) upon PHA-stimulated prolifer­
ation and the consequent effect of 2-ME. It clearly shows that DTNB 
had no effect even at high concentrations (2000 /AM). Furthermore, 
2-ME itself inhibited proliferation almost completely at a concent­
ration of 500 /AM. Similar results were achieved with PWM-stimul- 
ated proliferation (data not shown). To see if the inhibition caused 
by the high 2-ME concentration was due to toxicity, the viability of 
cells incubated for 3 days with 2-ME was examined by trypan-blue ex­
clusion which showed>707o cell death at 500 /aM 2-ME. At 100/a M 
2-ME, no significant toxicity was observed by this method. The next 
potential SH-oxidising agent used was oxidised glutathione, results 
for which are shown in Fig. 17. Again, no inhibition was found 
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FIG.16. Effect of preincubation with DTNB on PBMC proliferation
in response to PHA (1 ^igml”^) in the presence and absence 
of 2-ME. Each data point represents the mean value of 
3 experiments (standard deviation bars omitted for clarity)
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FIG.17. Effect of preincubation with oxidised glutathione on PBMC
proliferation in response to PHA (1 ^gml"^) in the presence 
and absence of 2-ME. Each data point represents the mean 
value of 3 experiments (standard deviation bars omitted 
for clarity).
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as was the case with PWM-induced proliferation (data not shown).
The toxic effect of 2-ME at 500 flM was again observed.
At this point, the proliferation assay, initially used due to
the relatively short experimental times involved, was discontinued. 
Instead, PWM-induced IgG synthesis was assayed to determine if this 
was more sensitive to the action of thiol-blocking agents. Initial 
experiments showed a 1/200 dilution of PWM to give an optimum res­
ponse (Fig. 18) although dilutions of 1/40 and 1/1000 were also 
used where sufficient numbers of cells were available. Only small
amounts of IgG were generated in the absence of PWM ( <  250 ng
per million cells per ml).
The failure of DTNB and oxidised glutathione to produce in­
hibition of IgG synthesis at any significant level are shown in 
Tables 8 and 9 respectively. The capacity of D-penicillamine to 
form disulphides in the presence of some metal ions was the ration­
ale behind the use of D-penicillamine with Cuf* ions as the next 
potential reversible SH-oxidising agent. The effects of pre- incu­
bating mononuclear cells with D-penicillamine/Cu^'*’ are shown in 
Fig. 19. The observed inhibition at D-penicillamine concentrations 
exceeding 50 ^»»Joccurred irrespective of the presence of 2-ME in 
culture at concentrations up to 100 Experiments performed in 




FIG.18. Effects of different dilutions of PWM upon 
induction of IgG synthesis in PBMCs.
- Q 2 -
(DTNB) 
( /iM)
- 2 ME 
(100 /iM)
IgG Production ng per 1 x 10^ cells
0 - 2460 - 255
0 2385 - 310
100 - 2400 - 290
100 + 2315 - 205
1000 - 2240 - 310
1000 + 2355 - 360
TABLE 8 . Effect of pre-incubation with DTNB on IgG synthesis
by PBMCs (4B W M ) in the presence or absence of 100 ^M 
2-ME. Results shown are mean IgG productions 






IgG production ng per 1 x lO^cells
0 - 2395 - 315 '
0 + 2320 - 290
100 - 2270 - 250
100 + 2355 - 380
500 - 2230 - 210
500 + 2265 - 385
TABLE 9 Effect of pre-incubating with oxidised glutathione 
upon IgG synthesis by PBMCs (+ PWM) in the presence 
or absence of 100 /iM 2-ME. Results shown are mean 








FIG. 19. Effect of D-penicillamine and ions upon
IgG synthesis by PBMCs in resDonse to PWM.
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A.B .PRODUCTION OF BY PENICILLAMINE AND IONS
The ability of D-penicillamine and Cu^* ions to generate H^Og 
was investigated using the phenol red oxidation micro-assay. Various 
concentrations of D-penicillamine (10 - 250 jugml”^) were incubated
with or without 8 [iM Cû '*’ ions (in the form of CuSO^) at 37°Cfor 5 
minutes after which time phenol red buffer solutions containing HRPO 
were added for a further five minutes. Absorbance changes were moni­
tored by reading the plates in a micro-ELISA reader at 610 nm. Figure 
20 shows the generation of by D-penicillamine in the presence of
copper. The results show a biphasic effect with maximal product­
ion being seen with 100 pigml ^ D-penicillamine. At 250 jLlgnil"̂  D-peni­
cillamine there is a substantial drop in production compared with
100 /igml ^ D-penicillamine. When copper was absent, no H^O^was pro­
duced. The phenol red oxidation was shown to be due to only
since control experiments in which catalase (1500 Uml”^) was added 
failed to exhibit phenol red oxidation. These results demonstrate 
the ability of D-penicillamine to form in the presence of copper.
The failure of these studies to find a suitable reversible SH- 
blocker led to the use of the irreversible SH-blocking agent, pHMPSA, 
used in the original experiments by McKeown et al (1984a) in con­
sequent experiments. Pre-incubation with pHMPSA results in a dose- 
dependent inhibition of PWM-induced IgG synthesis (Fig.21). 50%
inhibition (ID^^) was estimated to be about 15 /iM pHMPSA. No re­
versal of this inhibition was observed upon addition of 2ME (50 and 
100 /iM) (data not shown).
4.C. EFFECT OF SH BLOCKADE UPON ANTIGEN/PWM PRESENTATION BY MONOCYTES 
The accessory function performed by monocytes in the immune
response in vitro is complex and not fully understood. It is known
that PWM-induced IgG synthesis is absolutely dependent upon intact
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FIG. 20 . The generation of by D-penicillamine in
the presence of Cu2^ ions (8 /iM). Exoeriments 
where ions were omitted failed to produce
H^O^. Results expressed are means of 4 experiments,
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FIG.21. Effect of preincubation with pHMPSA upon PBMC I#G 
synthesis. Each histogram represents the mean of 
4 experiments (- l.s.d.) ID^^ of pHMPSA was estimated 
to be 15 llM.
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1984a). The ability of monocytes to present antigen, in assoc­
iation with Class II MHO antigens, and their production of the cyto­
kine, IL-1 are necessary for an effective immune response. It has 
been shown that lymphocytes form characteristic clusters around mono­
cytes in response to soluble antigens in vitro (Werdelin et al,
1974; Powell et al, 1980). These clusters are thought to represent 
antigen presentation by the monocytes to the lymphocytes since they 
do not form in the absence of antigen. Physical interactions between 
the cells can be observed by both light and electron microscopy. To 
see if antigen/PWM presentation by monocytes was SH-dependent, the 
ability of lymphocytes to cluster around monocytes in response to 
these stimuli after pre-incubation with pHMPSA was assayed. Normal 
(untreated) and SH-blocked lymphocytes were added back in reconstit­
ution experiments to blocked or unblocked monocytes which had been 
pulsed with PWM. Cluster formation was assessed by light microscopy - 
the results are given in Fig.22. Both these results and those of the 
controls which omitted monocytes/lymphocytes ruled out an adhesive 
effect. Therefore, it appears that antigen/PWM presentation by mono­
cytes is not SH-dependent. Similarly, lymphocytes do not require free 
SH groups to recognise antigen/PWM on monocytes.
The production of IL-1 by monocytes was not assessed in this 
work as previous studies by other workers indicated that its prod­
uction did not require free SH groups (McKeown et al, 1985b; S.F. 
Chai, personal communication).
The exact biochemical events occurring at the monocyte cell 
surface necessary for their accessory function in the immune res­
ponse have yet to be fully defined and the situation appears complex. 
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FIG.22. Cluster formation by monocytes and lymphocytes in
response to PWM (# ) and FED (O ). Cells were treated 
with pHMPSA to block surface SH groups (+) or were 
left untreated (-).
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intracellular Ca^^ion mobilisation, activation of phospholipase 
and the subsequent generation of arachidonic acid derived products 
e.g. prostaglandins and leukotrienes, and oxidative metabolism.
Further experiments were performed to determine the requirement of 
free cell-surface SH groups in some of these monocyte functions.
4.D. EFFECT OF SH-BLOCKADE UPON Ca^+ ION MOBILISATION
PHA-induced Ca^^ ion mobilisation in mononuclear cells was 
monitored by use of the quinoline derivative, Quin-2 which fluoresces 
upon chelation of Ca^* ions due to a conformational change. The ex­
periments used whole mononuclear cell preparations due to the large 
numbers of cells required. Both untreated cells and those whose sur­
face SH groups were blocked by pHMPSA showed similar responses to PHA 
in all cases. Fig. 23 is an actual trace obtained from one subject's 
cells, both blocked and unblocked. These results indicate that block­
ade of cell surface SH groups has no effect upon intracellular Ca^* 
ion mobilisation.
4.E. EFFECT OF SH-BLOCKADE UPON ^(H)-OLEIC ACID UPTAKE BY MONONUCLEAR 
CELLS.
Some arachidonic acid derived products are known to have reg­
ulatory effects upon the immune response e.g. PGE^ (Goodwin et al, 
1977; Staite and Panayi, 1982; Jellinek et al, 1985). Free arach­
idonic acid is generated from membrane phospholipids by the action of 
phospholipase A^. One of the regulatory reactions controlling the 
level of free arachidonic acid available for further metabolism is its 
reacylation back into membrane lipids by acyl-transferase enzymes 
(Kroner et al, 1981). The effect of SH blockade upon this acylation 
capacity was determined by measuring the uptake of tritiated oleic 
acid into mononuclear cells. As fig. 24 shows, incorporation of 
^(H) oleic acid was inhibited in a dose dependent manner by pHMPSA
-101-




FIG,23. Actual trace showing Ca^^ ion mobilisation by PHA
in normal PBMCs and PBMCs with blocked SH groups. 
All subjects showed similar traces and no effect 
was observed with SH blockade. Arrow represents 



















FIG.24. Effect of preincubation with pHMPSA upon 
incorporation of ‘̂(H) oleic acid by PBMCs 
Each histogram represents mean - 1 s.d. 
in = 5)
-103-
at concentrations exceeding 10 At this lower concentration, 
however, a slight stimulation was observed. In these experiments, 
the cells were not washed following pre-incubation with pHMPSA. 
Subsequent experiments, however, in which cells were washed three 
times in RPMI + 1% fatty acid poor BSA after this pre-incubation was 
completed, failed to show inhibition by pHMPSA even at 100 /XM as 
shown in Fig. 25. So, the ability of mononuclear cells to take up
3
(H)-oleic acid into their membranes by acylation is inhibited by 
blockade of cell surface SH groups; however, this effect is trans­
ient and can be overcome by washing the cells.
4.F. EFFECT OF NDGA UPON PWM-INDUCED IgG SYNTHESIS
There is some evidence to suggest that the lipoxygenase pathway 
of neutrophils might be SH-dependent (C. Maslen, PhD thesis,1985) 
since pHMPSA can inhibit the formation of lipoxygenase-derived hydro­
peroxides. Experiments were carried out to determine if lipoxygenase 
products e.g. LTB^ are necessary for IgG synthesis by assaying the 
effect of a known lipoxygenase inhibitor, nor-dihydroguaiaretic acid 
(NDGA). The results are shown in Fig. 26. NDGA causes inhibition 
of PWM-induced IgG synthesis in a dose-dependent fashion with an ID^q 
estimated to be about 20 flM. This was not due to a toxic effect since 
cell viability, as assessed by trypan blue exclusion, was not affected 
by incubation for 7 days with the highest dose of NDGA used. It is
important to note, however, that in this concentration range of NDGA,
the compound is thought to have anti-oxidant effects which might be 
responsible for the observed inhibition. The results provide evi­
dence that products of the lipoxygenase pathway might be involved in 
regulation of the in vitro immune response.
The previous evidence raised ̂ he possibility that blockade of 










FIG.25. Effect of preincubation with pHMPSA (100 /iM) upon 
the ability of PBMCs to incorporate ^(H) oleic acid. 
Cells were washed 3 times after preincubation (*) 
or unwashed (no asterisk). Each histogram represents 
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FIG.26. The effect of Nor-dihydroguaiaretic acid (NDGA) upon 
IgG synthesis. Each histogram represents mean in­
hibition produced by NDGA (- l.s.d.) (n = 4). ID, 
was estimated to be 20^M.
50
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by inhibiting the generation of essential lipoxygenase products.
This hypothesis was tested by investigating the ability of exogenous
leukotriene B, (LTB,) to overcome inhibition of the in vitro immune 4 4 ---------
response caused by SH-blockade of monocytes. Monocytes, preincub­
ated with pHMPSA, were reconstituted with untreated lymphocytes in 
the presence of 10 nM LTB^ and PWM-induced IgG synthesis measured 
by ELISA. The results are shown graphically in Fig. 27 and they 
clearly show the inability of LTB^ to overcome the inhibition. No 
effect upon IgG synthesis by LTB^ was observed in normal cultures 
(Fig. 27). In control experiments without PWM, low levels of IgG 
( < 3 0 0  ng per million cells per ml.) were produced both in the ab­
sence and presence of LTB^.
4.G. EFFECT OF SH BLOCKADE UPON MONOCYTE OXIDATIVE METABOLISM
In response to various immunological and chemical stimuli, mono­
cytes produce oxygen-derived free radicals. The effect of SH block­
ade upon monocyte oxidative metabolism and the possible role of this 
in the cell’s accessory function were investigated. Monocyte super­
oxide anion production in response to heat-aggregated IgG (HAGG) was 
measured by a ferricytochrome C reduction assay. The results are 
given in Table 10. They clearly show that SH blockade of monocytes 
by pHMPSA totally abolished their ability to produce superoxide anion, 
Other studies by Maslen (1985) have shown ^2^2 Production by mono­
cytes to be similarly affected by pHMPSA with an ID^^ of about 10 fiM, 
For these reasons, similar experiments to those conducted using exog­
enous LTB^ were carried out to see if ^2^^2 able to reverse pHMPSA- 
induced inhibition of the immune response. ^2^2 (concentration 
range 20 nM to 2000 nM) was added to cultures with untreated mono­
cytes and where monocytes had been blocked by pHMPSA. Figures 28 









FIG.27. Effect of LTB^ upon IgG synthesis by control PBMCs 
with normal monocytes (-pHMPSA) and monocytes with 
surface SH grouos blocked (-«-pHMPSA) in the presence 
of PWM. Each histogram represents mean IgG production 
(-l.s.d.) (n = 4)
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TREATMENT n moles cyt C reduced/ 
2 X 10^ cells/30 mins
-pHMPSA 
+pHMPSA (50jLlM)
3.30 - 0.9 
0.00
TABLE 10. Effect of pHMPSA upon superoxide production
by monocytes; (n = 3)
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FIG.28. The effect of hydrogen oeroxide upon IgG synthesis by 
control PBMCs with normal monocytes (-pHMPSA) and 
monocytes with surface SH groups blocked (+ pHMPSA) 
in the presence of PWM. Each histogram represents 
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FIG.29. The effect of hydrogen peroxide upon IgG synthesis by 
control PBMCs with normal monocytes (-pHMPSA) and 
monocytes with surface SH groups blocked (+pHMPSA) 
in the absence of PWM. Each histogram represents 
the mean IgG production (- l.s.d.) (n = 5)
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and absence of PWM. The results in Fig. 28 demonstrate that 
causes a slight enhancement of the normal PWM response at low 
concentrations (20 nM) whilst at 2000 nM H^O^ itself produces an in­
hibition of the in vitro immune response. Evidence for the ability 
of H^O^ at low concentrations to be mitogenic itself is provided 
by cultures performed in the absence of PWM results in Fig. 29 
which show elevated IgG production in the presence of 20 nM
4.H. H^O^ PRODUCTION BY MONOCYTES FROM NORMAL SUBJECTS AND R.A.
PATIENTS
Although the results above demonstrated the inability of H^O^ 
to overcome inhibition of IgG synthesis by monocyte SH-blockade, 
it was decided to assay the production of H^O^ by both normal and 
rheumatoid monocytes since H^O^ itself had been shown to have effects 
on IgG synthesis in the presence and absence of PWM. FMLP (formyl- 
methionyl-leucyl-phenylalanine) was chosen as the stimulus since it 
had been previously shown that stimulation of monocytes produces 
only and not other peroxides (Maslen, 1985). This observation
was verified in these experiments since catalase totally abolished 
phenol red oxidation. Figs. 30 and 31 show production (with
and without pre-incubation with 5 x 10 ^M 2-ME) by normal monocytes, 
monocytes from RA patients on NSAIDs and monocytes from RA patients 
established on D-penicillamine in the absence of any stimulus (Fig. 
30) and in the presence of 5 x 10 ^M FMLP (Fig. 31) which prelim­
inary experiments had shown to give maximal production. Pooled
data for these are given in Table 11. Stimulated production
values represent corrected values where unstimulated values have
-5been subtracted from stimulated values. Pre-incubation with 5 x 10 M 
2-ME did not significantly alter production in any of the groups















FIG.30. Spontaneous hydrogen peroxide production by monocytes 
from normal healthy controls, RA patients on NSAIDs 
and RA patients on D-penicillaimine. in the presence ( + ) 














FIG.31. Hydrogen peroxide production by monocytes from normal
healthy controls, RA patients on NSAIDs and RA patients 
on D-penicillamine in response to 5 x 10~^MfMLP (corrected 
for unstimulated values) in the presence (+) and absence 
(-) of 5 X 10"^ M 2-ME.
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GROUP n moles H^O^/ 2 X lO^cells
UNSTIMULATED STIMULATED
median (range) median (range)
-2ME +2ME -2ME +2ME
Controls 0.495 0.560 1.135 1.175
(n = 8) (0.00-0.64) (0.00-0.96) (0.60-2.82) (0.32-2.78)
RA - NSAID 1.210 1.245 1.905 1.515
(n = 14) (0.45-3.90) (0.67-3.90) (0.25-3.50) (0.42-3.81)
RA - D-pen 0.990 1.185 1.975 1.660
(n = 8) (0.45-2.49) (0.54-3.52) (0.28-4.16) (0.32-3.38)
STATISTICAL ANALYSIS
No statastical difference was observed between - 2ME for either 
unstimulated or stimulated monocytes in any group (Wilcoxons Ranking
Sum test >  0.5) 
Mann-Whitney U Test
s = significant 
ns = non-significant
-2ME Unstimulated monocytes
RA - NSAID vs. controls P <  0.01 (s)
RA - D-pen vs. controls P <  0.05 (s)
RA - D-pen vs. RA-NSAID P >  0.5 (ns)
-2ME Stimulated monocytes
RA - NSAID vs. controls P >0.05 (ns)
RA - D-pen vs. controls P >0.05 (ns)
RA — D-pen vs. RA-NSAID P >0.5 (ns)
+2ME Unstimulated monocytes
RA - NSAID vs. controls P < 0 . 0 1 (s )
RA - D-pen vs. controls P < 0 . 0 5 (s)
RA - D-pen vs. RA-NSAID P > 0 . 5 (ns)
+2ME Stimulated monocytes
RA - NSAID vs. controls P > 0 . 5 (ns)
RA - D-pen vs. controls P > 0 . 5 (ns)
RA — D-pen vs. RA-NSAID P > 0 . 5 (ns)
TABLE 11. Pooled data and statistical analysis for H O  production
by monocytes from normals, patients upon NSAIDs 
(RA-NSAID) and patients upon D-penicillamine (RA-D-pen)
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Sum Test, p >0.5). Statistical analysis comparing the different 
monocyte groups was performed using the Mann-Whitney U test. Un­
stimulated monocytes from RA patients on NSAIDs (RA-NSAID) and on 
D-penicillamine (RA-D-pen) produced significantly higher amounts of 
^2^2 healthy monocytes both with and without treatment with 2-ME.
(RA-NSAID vs. controls p<0.01; RA-D-pen vs.controls p <0.05).
There was no significant difference between spontaneous H^O^ product­
ion by RA-NSAID and RA-D-pen monocytes either with or without 2-ME 
treatment (p>0.5). When stimulated with FMLP, both RA-NSAID and 
RA-D-pen monocytes produced greater amounts of than control cells;
however, these differences failed to reach significance either with­
out 2-ME (RA-NSAID vs. controls, p >0.05; RA-D-pen. vs. controls, 
p>0.05), or with 2-ME (RA-NSAID vs. controls, p>0.5; RA-D-pen. 
vs. controls, p>0.5).
Figures 30 and 31 show that there was considerable intersubject 
variability in the production of H^O^ both spontaneously and upon 
stimulation with FMLP with the exception of the unstimulated control 
monocyte group. These data also show that the effect of 2-ME varied 
quite considerably between different subjects with some showing quite 
substantial increases upon 2-ME pre-incubation and others demonstrat­
ing decreased production.
4.1. EFFECT OF CATALASE UPON IgG PRODUCTION
The finding that RA monocytes produced increased amounts of 
led to experiments to investigate the effect of catalase upon 
IgG production. Peripheral blood mononuclear cells from RA patients 
on NSAIDs and from control subjects were incubated for 7 days with 
and without PWM either in the absence of presence of catalase 











FIG.32. Effect of adding catalase (300 Uml”^) upon 
IgG synthesis by normal and rheumatoid PBMCs 
upon stimulation with PWM.
( + ) = cultures with catalase 
( - ) = cultures without catalase
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Normal cells produced significantly greater amounts of IgG 
than rheumatoid cells both with and without catalase (Mann-Whitney 
U test; p <  0.05). There were no statistically significant 
differences in IgG synthesis in either group in the presence of 




5.A.HPLC DEVELOPMENT AND PHARMACOKINETICS OF PENICILLAMINE
The analysis of penicillamine (and its metabolites) in bio­
logical fluids has been a complex problem that has presented a tre­
mendous challenge to workers in the field for many years. This is 
because;-
(i) The penicillamine molecule lacks a chromophore so ruling 
out ultra-violet spectrometry for detection.
(ii) It is very reactive i.e.
(a) strongly protein bound
(b) forms disulphides at neutral pH especially in the presence 
of trace metals.
(c) forms chelates with metal ions
(d) highly water-soluble and, so, cannot be extracted into 
organic solvents.
(e) decomposes when aqueous solutions are concentrated under 
vacuum.
Only in recent years have procedures been adopted which have elimin­
ated these problems in penicillamine analysis. These have been 
mainly the use of EDTA to chelate any metal ions present, so prevent­
ing oxidation and chelation, and manipulation of the pH to keep the 
drug in its desired form (Bergstrom et al, 1980).
The analytical methods devised for penicillamine and its meta­
bolites to date can be broadly divided into non-chromatographic tech­
niques and chromatographic assays.
The non-chromatographic procedures basically comprise spectro- 
metric assays and radio-immunoassays (RIAs). The former, such as 
those devised by Pal (195.9) and Mann and Mitchell (1979), exhibit 
low sensitivity and, since they utilise the drug’s sulphydryl group, 
lack specificity because they fail to distinguish between endogenous 
thiols and the drug. The RIA developed by Assem and Vickers (1974),
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whilst specific for penicillamine, is limited in its applications 
by the need to produce specific antibodies and relative inavailab­
ility of radiolabelled drug. {For disulphide anlaysis, specific 
antibodies and radiolabelled compounds are required). So, non­
chromatographic approaches have serious limitations.
Recently, most procedures for penicillamine analysis have been 
of a chromatographic nature. Gas-liquid chromatographic methods have 
proved unsuccessful mainly due to complex sample preparation i.e. 
extraction procedures followed by derivatision due to the small size 
of the molecules involved (Jellum et al, 1969; Kucharchyk and 
Shahinan, 1981). A number of methods using amino-acid analysers 
or ion-exchange chromatography coupled with ninhydrin detection have 
been developed for determination of the drug and its metabolites. How­
ever, their application to routine analysis is limited by the long 
analysis times involved which are at least 8 hours per sample (Pur- 
die et al, 1968; Perrett et al,1976; Hsuing et al, 1978, Muijsers 
et al, 1979).
In the last 1970s, Rabenstein and Saetre developed a HPLC- el­
ectro-chemical detection method which analysed D-penicillamine by 
use of a mercury-based electrode specific for SH-containing compounds 
(Rabenstein and Saetre, 1977; Saetre and Rabenstein, 1978). The 
method utilised non-commerical custom-made detectors which proved to 
be a drawback. However, it has provided the basis for a number of 
subsequent techniques developed using the sort of detection (Berg­
strom, Kay and Wagner, 1981; Kreuzig and Frank, 1981). The methods 
have been used to measure reduced penicillamine in bilogical fluids.
In this study, total plasma D-penicillamine was determined for the 
following reasons. The active form of D-penicillamine in RA remains 
uncertain. It appears that the vast majority of D-penicillamine in
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the plasma is protein bound, mostly to albumin by means of covalent 
disulphide bonds (Planas-Bohne, 1981; Perrett, 1981). The ability 
of D-penicillamine to undergo thiol-disulphide exchange reactions 
means this protein-bound D-penicillamine is potentially available 
for its pharmacological action. Thus, it was considered appropriate 
to perform pharmacokinetic studies determining total levels of the 
drug in the plasma. The method devised in this project, as the res­
ults show, is sensitive and very reproducible. Moreover, it is fairly 
simple to operate and permits throughput of at least 9 samples in dup­
licate plus the necessary standards in the average working day due 
to the rapid analysis time, thus, rendering it suitable for pharmaco­
kinetic studies such as those undertaken in this project.
Previous studies have indicated that the absorption of D- 
penicillamine is reduced when taken with food by about 20% in rats 
(Planas-Bohne, 1972) and about a third in man (Perrett, 1981). Both 
these studies employed indirect methods to measure the drug, the 
former using radio-labelled drug and the latter by measuring urinary 
metabolites only. The study in this thesis, using HPLC to determine 
plasma drug concentrations, has shown that the drug's bioavailability 
is significantly reduced following a light meal in agreement with 
the above studies. Other workers have produced similar results. 
Muijsers et al (1984) measured the bioavailability of total D-penic­
illamine similar to this study whilst some studies have measured 
free (reduced) drug. (Bergstrom et al, 1981; Schuna et al, 1983). 
Only one study has suggested that food has no effect upon penicilla­
mine absorption (Bucknall, Rabenstein and Ng. 1982); however, this 
was only a single case study and, perhaps, in the light of the weight 
of opposing evidence ought not to be considered the normal state 
of affairs.
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Since the time to attain maximum plasma drug concentrations 
in fasting and non-fasting conditions was essential the same in this 
investigation, this suggests that food does not inhibit the intrin­
sic absorption of penicillamine, but, more likely, removes the drug 
from the site of absorption. This conclusion was also drawn by 
Schuna and co-workers (1983). This is readi^ explained by the known 
chemical reactions in which penicillamine can participate e.g. 
chelation of metal ions, protein binding and oxidation to disulphides 
catalysed by metal ions. Perfusion work by Perrett (1981) suggests 
that formation of the internal disulphide by penicillamine during 
its passage through the gastro-intestinal tract would result in 
little absorption of the drug. The only major penicillamine compound 
found in the faeces is the internal disulphide (Perrett, 1981). 
Muijsers et al (1984) have demonstrated that simultaneous administ­
ration of oral iron preparations with D-penicillamine produces an 
even more dramatic reduction in absorption of the drug. Indirect 
evidence for this also comes from Lyle and colleagues (1977) 
who showed D-penicillamine-induced cupruresis was inhibited by oral 
iron, and by Hall et al (1981) who demonstrated a similar effect upon 
D-penicillamine-induced serum thiol reactivity. These studies suggest 
that either iron-chelation by penicillamine or iron-catalysed peni­
cillamine disulphide formation are probably responsible for reduced 
D-penicillamine absorption with oral iron.
Chronic administration of the drug with food is likely to res­
ult in lower plasma concentrations at steady state compared with 
that obtained when taken in the fasting state. Hill (1979) has rep­
orted that patients receiving penicillamine with meals had a lower 
incidence of side effects and withdrawals due to adverse reactions 
than patients taking the drug without food. In both cases, clinical
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efficacy was equivalent. This might suggest that patients who 
received the drug whilst fasting attained higher plasma drug con­
centrations which perhaps exceeded a "toxicity threshold" i.e. per­
haps plasma levels may contribute to penicillamine toxicity. Unfort­
unately, no monitoring of drug levels was performed in this study 
presumably due to the lack of an appropriate analytical method.
Many RA patients take iron supplements for the anaemia seen 
in the disease; in these patients simultaneous administration of 
such preparations with penicillamine may result in plasma drug con­
centrations insufficient to produce a clinical effect. Thus, oral 
iron preparations should not be given to RA patients taking penicil­
lamine or, at least, not given at the same time.
The pharmacokinetics of penicillamine in both normal volunt­
eers and RA patients have been studied. The observation that peak 
plasma concentrations occur at about 2 hours agrees well with the 
results obtained by other workers (Patzschke et al, 1977; Saetre 
and Rabenstein, 1978; Wiesner et al, 1981; Bergstrom et al, 1981 
Butler et al, 1982; Kukovetz et al, 1983; Muijsers et al, 1984).
A number of pharmacokinetic studies by these workers have measured 
free, reduced D-penicillamine only (Saetre and Rabenstein, 1978, 
Wiesner et al, 1981; Bergstrom et al, 1981; Butler et al, 1982; 
Kukovetz et al, 1983; Schuna et al, 1983). In this study, total plas­
ma D-penicillamine concentrations have been determined for the reas­
ons previously expounded. One other group of workers have also dir­
ectly measured total D-penicllamine in the plasma (Muijsers et al , 
1979). In their studies they have shown that penicillamine ex­
hibits a biphasic decay in the plasma with values of 1.6 - 3 hours 
for the rapid elimination phase followed by a slower decline of 
about 4 - 6  days (Muijsers et al, 1979; Vander Korst et al, 1981;
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Muijsers et al, 1984). Similar results were found in a study 
using ^^C-labelled D-penicillamine (Patzsche et al, 1977). The 
values obtained by these workers do not vary greatly from those ob­
tained in this study. Although the slow elimination phase reported 
here is shorter than those in the previously mentioned studies, the 
value found here, as outlined in the results section, can be criti­
cised and may well be shorter than the actual value.
Those workers measuring free, reduced penidlJamine have also 
found rapid initial half-lives for D-penicillamine varying from 
1 to 5 hours (Russell et al, 1979, Bergstrom et al, 1981, Wiesner 
et al, 1981; Butler et al, 1982; Kukovetz et al, 1983). In these 
studies, no slow elimination phase was reported.
In those studies where total D-penicillamine was measured, 
including this one, the observation of two half-lives suggests the 
presence of at least 2 pools, one rapid pool with a half-life of a 
few hours and a slow pool with a half-life in the order of several 
days. This slow pool may be due to sequestering of the drug in tis­
sues from which the plasma pool is constantly refilled. The initial 
half-life observed for free-drug is similar to total drug although 
perhaps slightly more rapid. This may be because this half-life 
is probably the oxidation of the free reduced drug as opposed to 
actual loss from the plasma compartment.
The observed peak plasma concentrations showed considerable 
intersubject variability. This has been found in most of the other 
studies whether measuring total or free drug. Van der Korst et al, 
(1981) measuring total D-penicillamine found a peak plasma drug 
level of about 5 ^gml”^ for an oral dose of 250 mg. whilst for a 
dose of 500 mg. it was approximately 10 jU-Çml ^ . When compared to 
the values obtained in this work of 2.3 pigml”^ for a 125 mg. dose
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(RA patients) and about 8 ^igml  ̂ for 500 mg. (volunteers, fasting
state), the two sets of data seem quite compatible. Other studies
measuring free penicillamine have shown peak plasma levels lower
than these as expected. Wiesner et al, (1981) found that an 800 mg.
oral dose gave a péak value of about 4 j[(gml"̂  in normal volunteers.
Kukovetz and associates (1893) found an average peak concentration
in plasma of 0.9 /igml ^ for 250 mg. penicillamine whilst Schuna £t
al, (1983) reported a value of 3 jUgml ^ for a 500 mg. oral dose in
normal subjects. Bergstrom et al (1981) found peak levels ranging 
-1 -1between 3 />(gml and 5 /igml for a 500 mg. oral dose in 5 healthy
subjects. A two subject study by Russell and colleagues (1979) found
-1 -1values of 0.5 /Igml for 250 mg. and 2 ^gml for 750 mg. penicil­
lamine.
Taken altogether, these results indicate that free penicillamine 
in plasma constitutes between 10% and 50% of the total drug when 
administered initially with a mean value of about 25%. In his re­
view on penicillamine metabolism, Perrett (1981) has suggested that 
free penicillamine constitutes about 6% of the total plasma peni­
cillamine. This figure is derived mainly from studies measuring 
drug levels in RA patients and cystinurics who were stabilised on 
the drug and not receiving it for the first time. The inherent re­
activity of penicillamine may explain this apparent discrepancy i.e. 
as the drug initially enters the plasma, a considerable amount of 
it i.e. about 25% remains in the free form, but, as more drug enters 
the plasma and the longer it remains there, more of it oxidises 
causing a drop in the level of free drug to a steady basal level 
e.g. 6%.
Another explanation is also possible. In the studies measur­
ing free drug, acid precipitation was used to obtain a non-protein
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fraction in which to measure free-drug. This assumes that penicil­
lamine is protein-bound by means of covalent disulphide bridges un­
affected by acid treatment. However, if some drug is ionically 
bonded to proteins, such treatment would release the drug and keep 
it in the reduced form due to the acidic pH, so giving falsely high­
er values for free drug. Perhaps, a more preferable way to obtain 
a non-protein fraction is by ultrafiltration. Indeed, when this 
method was employed by Abounassif and Jefferies (1983) to measure 
free drug,very low levels of free drug were found ( < 1 % ) .  It should 
prove interesting to compare values for free drug from the same 
samples obtained by ultrafiltration and acid precipitation to see 
if differences exist.
The identity of the pharmacologically active form of D-peni­
cillamine is still unknown although most authors suggest either the 
free thiol form or a copper-penidllamine complex is responsible for 
its action in RA. The reported levels for free drug are low even 
in patients stabilised on high doses e.g. Brooks et al, (1984) 
found a mean value of 3.7 jLlgrnl”  ̂ free D-penicillamine in patients 
taking 750 mg. after one year. It seems unlikely that such low con­
centrations can provide the therapeutic effects of the drug. The 
ability of D-penicillamine to participate in thiol-disulphide ex­
changes suggests that plasma protein-bound drug is potentially avail­
able for its pharmacological actions. The disulphides that D-peni­
cillamine forms with itself and cysteine etc. may be active forms 
per se although there is no evidence to support this idea.
Both this study and those by Muijsers’ group (Muijsers et al, 
1979; Van der Korst et al,1981; Muijsers et al, 1984) have shown 
the existence of two pools of D-penicillamine. This slow pool does 
not reflect binding to plasma albumin since total D-penicillamine
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was measured, but, is probably due to sequestration in tissues 
perhaps by protein binding. Since this is reversible then even 
this tissue pool is available for pharmacological actions. Muijsers 
and colleagues have shown that the deep pool is not easily saturated 
and suggest that, perhaps, therapeutic benefit is derived upon sat­
uration of this pool - this would account for slow onset of clinical 
effect of the drug. There is no direct evidence that D-penicillamine 
accumulates in the connective tissues in humans although Planas- 
Bohne (1981) has shown that in rats, D-penicillamine is taken up by 
tissues especially of those with high collagen contents.
The method devised in this project has been used to investi­
gate the initial pharmacokinetics of D-penicillamine in both normal 
volunteers and RA patients. Work is currently in progress using 
the method to follow up the total D-penicillamine plasma concentrat­
ions of RA patients to steady state kinetics to see if a correlation 
exists between plasma levels of the drug and its clinical efficacy/ 
toxicity. Table 12 (courtesy of Dr. L.J. Notarianni) shows total D- 
penicillamine plasma concentrations at steady state. Patients whose 
dose was increased at intervals of less than 7 days did not achieve 
steady state conditions on a particular dose (Notarianni, personal 
communication). This observation is compatible with the calculated 
slow half-life from the initial pharmacokinetic study presented in 
this thesis since it is generally accepted that steady-state con­
ditions are achieved after 5 terminal half-lives.
Thus, clinicians who prescribe D-penicillamine for RA patients 
should wait at least 7 days and probably much longer before increas­
ing the prescribed dose in order to see if toxic side effects are 
manifest at a particular dose. Clinical efficacy and observed tox­
icity are now being related to these steady-state drug levels. Two
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Daily Dose D-Penicillamine Plasma Concentration at SS (Range) /^g/ml.
125 mg. 5.12 - 0.24 (1.72 - 8.44) n=53
250 mg. 8.55 - 0.59 (5.41 - 14.10) n=24
375 mg. 9.89 - 0.10 (5.28 - 16.41) n=10
500 mg. 12.94 - 1.18 (8.60 - 17.17) n= 7
TABLE 12 . Total D-Penicillamine Plasma Concentrations at 
Steady State (n values represent number of 
observations at each dose)
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very recent studies, one measuring free drug (Brooks et al, 1984) 
and one measuring total drug (Muijsers et al, 1984) have failed to 
find any correlation between D-penicillamine levels and efficacy/ 
toxicity. This would seem to exclude the possibility that lack of 
clinical response is due to defective intestinal absorption of the 
drug. Both these studies emphasised that some of the most common 
side effects observed with D-penicillamine therapy, proteinuria and 
thrombocytopenia, were not connected to high drug levels. An ear­
lier preliminary observation by Van der Korst et al, (1981) showing 
that a correlation existed between serum cysteine depletion and D- 
penicillamine induced side effects has been made marginal by their 
latest study of a larger group of patients (Muijsers et al, 1984).
It is highly desirable to obtain assays for metabolites of D- 
penicillamine (see Fig.33). Such assays would permit full metabolic 
profiles for RA patients to be determined and correlation studies 
may shed light on the mechanisms by which D-penicillamine exerts 
its clinical benefit and produces side effects e.g. patients who 
respond to D-penicillamine may show elevated levels of cysteine—D- 
penicillamine disulphide suggesting perhaps that this metabolite 
is an active form. The only truly "metabolised" form of D-penicil­
lamine, as yet identified, is the S-methyl derivative which has 
been detected in the urine of cystinurics taking D-penicllamine 
(Perrett, Sneddon and Stephens, 1976). The site of méthylation is 
thought to be the liver (Perrett, 1981). No satisfactory analyt­
ical procedure has been developed to measure this metabolite al­
though its presence in plasma has been detected (Muijsers et al, 
1979).
A recent study has tested the ability of RA patients on 
comparable doses of D-penicillamine to oxidise S-carboxymethyl
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L-cysteine (carbocysteine). (Emery et al, 1984). Patients were 
classified as either poor "sulphoxidisers" or extensive "sulphoxi- 
disers". There was a significant association betwen impaired sulph- 
oxidation and the manifestation of toxic side effects t<5 D-penicil­
lamine. Although these workers point out the structural similarity 
between D-penicillamine and carbocysteine, the similarity between 
the latter and S-methyl D-penicillamine is more marked. If this 
metabolite is responsible for toxicity, patients unable to oxidise 
it may produce side effects. Should this be true, then increased 
levels of S-methyl D-penicillamine in the plasma might usefully pre­
dict the development of toxicity as, indeed, would classification 
of a patient's sulphoxidation status.
Patients with Wilson's disease taking higher doses of peni­
cillamine than RA patients do not show a significantly enhanced in­
cidence of toxicity. Since the majority of D-penicillamine presum­
ably forms the copper chelate in Wilson's disease, it might suggest 
that this form of the drug does not contribute greatly, if at all, 
to the toxic side effects caused by the drug. One study, however, 
has shown that copper supplements given to RA patients are not 
prophalactic against toxicity (Andrews et al, 1973).
Finally, many studies attempting to elucidate the mechanism(s) 
by which D-penicillamine acts in RA have used in vitro model systems, 
particularly investigations on the immunological effects of the 
drug. A considerable number of these have reported effects with 
D-penicillamine at concentrations which, as these results and others 
show, are far in excess of those attained in vivo and extreme caut­
ion is warranted in the interpretation of such results.
-131-
5.B. SH-DEPENDENT REACTIONS OF MONOCYTES
McKeown et al (1984) have shown that the defective accessory 
function exhibited by rheumatoid monocytes when compared to normal 
monocytes is corrected in vitro by the addition of 2-ME whilst in 
vivo a similar improvement is achieved by successful treatment with 
D-penicillamine. These results suggest that the defect may be due 
to cell surface SH-oxidation. Attempts to find a reversible SH 
blocking agent to mimic the situation with rheumatoid monocytes, 
in order to study SH-dependent functions relevant to accessory fun­
ction as possible targets for D-penicillamine therapy,proved un­
successful. DTNB failed to produce significant inhibition upon 
pre-incubation with PBMCs. Although this contrasts with the observ­
ations of Chaplin and Wedner,(1978), these workers added the com­
pound directly to culture. Indeed, an additional experiment per­
formed in which DTNB was directly added produced total inhibition 
of PBMC proliferation at 1000 flM (data not shown). The possibility 
that these differences could be explained by prevention of lectin 
binding by DTNB itself cannot be ruled out. However, Chaplin and 
Wedner have shown that another inhibitory SH-blocking agent, dia­
mide, does not inhibit lectin-binding. Other conceivable explan­
ations include reversal of DTNB binding to the cells during the 
pre-incubation period before the addition of lectin.
Oxidised glutathione has been reported to inhibit mitogen- 
induced PBMC proliferation upon direct addition to culture due 
to the oxidation of cell surface SH groups (Johnson, 1980).
However, as with DTNB no marked inhibition was seen with this re­
agent. Again, reversal of glutathione binding might account for 
this result.
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D-penicillamine can act synergistically with copper ions 
to inhibit both mitogen-stimulated mononuclear cell proliferation 
and PWM-induced IgG synthesis in vitro as shown in this study and 
those by Lipsky (1981, 1984). Lipsky (1984) has proposed that this 
inhibition is due to suppression of T-helper lymphocyte function 
by hydrogen peroxide generated by the interaction of D-penicillamine 
with the Cu^^. However, Cu^^ ions are potent catalysts of di­
sulphide formation raising the possibility that Cu^* catalysed di­
sulphide formation between D-penicillamine and cell-surface SH 
groups may be responsible for the inhibition. This was the rationale 
behind the experiments performed here to use D-penicillamine/Cu^'*’ 
as a potential reversible SH-oxidising agent. No reversal of the 
inhibition of PWM-induced IgG synthesis was achieved with 2-ME 
perhaps suggesting that disulphide formation is not the underlying 
mechanism behind the inhibition. Thus, D-penicillamine/Cu^'*’ was 
not suitable for use as a reversible SH-blocking agent.
A number of different workers have claimed D-penicillamine is 
immunosuppressive in RA. This results from experiments showing 
inhibition of the in vitro immune response either with copper (Lipsky, 
1981; 1984) or without copper (Room et al,1979; Lewins et al,1982). 
However, the concentrations found to be inhibitory have been gener­
ally far in excess of those attained in vivo. In this study, marked 
inhibition of PWM-induced IgG synthesis was achieved at high con­
centrations (100 ^gml”^ and 250 ^gml”^) only. Pharmacokinetic 
studies measuring total drug show drug levels only approaching 
20 ptgml ^ after months of treatment (Muijsers et al, 1979; Muijsers 
et al,1984; Notarianni and Ferrie, personal communication using 
the method developed here). Further still, it is important to note 
that D-penicillamine is highly protein bound in vivo ( >  80%) and
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if free drug only is available for pharmacological purposes, then 
the drug concentrations used to produce in vitro inhibition are 
totally unrealistic when compared to the situation in vivo. The 
ability of D-penicillamine to generate hydrogen peroxide in vitro 
in synergy with Cuf^ ions is apparent from the results presented
here. (fig.20). This occurs at all concentrations with a peak
-1 -1occurring at 100 ^gml . At 250 jLtgml , there is a drop in appar­
ent production but one reason for this may be actual scaveng­
ing of by possibly an association with D-penicillamine Cu^^
ions. A similar scavenging of by D-penicillamine has been
demonstrated by Staite and colleagues (1984). The relevance of 
such scavenging to the mechanism of D-penicillamine in RA is called 
into doubt by the high concentrations needed to achieve such an 
effect. However, the relatively poor sensitivity of the assay may 
not monitor scavenging effects at lower concentrations of drug. 
Also, D-penicillamine (with copper) may act as a superoxide dis- 
mutase which may be relevant to its action in RA.
The failure to find a reversible SH-blocking agent led to 
the use of the irreversible blocking agent, para-hydroxymercuri- 
phenyl-sulphonic acid (pHMPSA) which was found to cause marked in­
hibition of PWM-induced IgG synthesis upon pre-incubation with the 
cells in agreement with the results of McKeown et al (1984a).
The immune response to most, if not all antigens requires 
processing and presentation of the antigens by specialised antigen- 
presenting cells (APCs) which in peripheral blood mononuclear cell 
cultures are probably the monocytes. The PWM response in vitro is 
absolutely dependent upon the presence of monocytes which suggests 
that PWM is probably presented by these cells in a fashion akin to 
antigens. Presentation of antigen to reactive T-lymphocytes by 
APCs occurs in association with antigenic protein determinants
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encoded by genes in the HLA-D region of the major histocompati­
bility complex in man (Moller,1978). Antigen presentation appears 
to involve an actual physical interaction between monocytes/macro­
phages and lymphocytes resulting in the formation of clusters in 
which several lymphocytes are attached to single monocytes in man 
(Werdelin et al, 1974; Powell et al, 1980). The finding that mono­
cytes and lymphocytes both require free cell surface SH groups for 
an effective immune response in vitro (McKeown et al, 1984a) and 
that D-penicillamine in association with copper apparently inhibits 
PWM-induced cluster formation (Hawkes and Kennedy,1984) led to spec­
ulation that antigen presentation and, hence, cluster formation might 
involve cell surface SH groups on both types of cell e.g. by for­
mation of disulphide bridges between them. However, the results 
presented in fig.22 clearly show that pHMPSA failed to inhibit clust­
er formation thereby excluding this hypothesis.
Maintenance of free surface SH groups during early stages of 
culture is essential for cellular activation in response to lectins 
(Chaplin and Wedner, 1978). The biochemical events occurring at the 
membrane upon stimulation appear to be complex and their precise 
nature is unclear. Among the early events likely to be involved are 
Ca^^ ion mobilisation, phospholipase activation and subsequent 
arachidonic acid metabolism, and oxidative metabolism.
Ca^^ ion mobilisation within the cytoplasm' appears to be 
important in the activation of many cell types, for example neutro­
phils (Smolen et al, 1982 ). The results in this study show clearly 
that free surface SH groups are not necessary for Câ '*’ mobilisation 
in response to PHA in mononuclear cells. It is unclear whether 
the increase in free cytoplasmic Câ '*’ concentration occurs as a 
result of fluxes across the membrane from the outside or from mobil-
-135-
isation of accumulated intracellular Ca^* ion stores. Should 
the latter be the case, then, the observation that free surface 
SH groups are not necessary is perhaps not surprising.
The role of arachidonic acid derived metabolites as regulators 
of the immune response is uncertain; however, a number of studies 
have demonstrated that PGE^, for example, can be immunomodulatory 
at least in vitro (Goodwin et al, 1977; Rappaport and Dodge, 1982; 
Jellinek et al, 1985). Corrigall and Panayi (1979) have shown that 
the depressed proliferative response exhibited by rheumatoid mono­
nuclear cells in vitro could be partially restored by the addition 
of indomethacin to the cultures. This suggests that excessive PGE^ 
production by monocytes may be responsible for the defective in 
vitro mononuclear cell function. Such a situation has been observed 
with murine cells (Metzger et al, 1980). The most direct approach 
to studying the sulphydryl-dependence of cyclo oxygenase activity 
would have been to assay prostaglandin production by monocytes with 
and without pHMPSA treatment. However, a number of practical cons­
traints precluded such a study. Prostaglandin production requires 
the liberation of arachidonic acid from membrane phospholipids by 
action of lipase enzymes (Irvine, 1982). The mechanisms of arach- 
idonate release and its regulation remain contentious (Irvine, 1982). 
Kroner et al (1981), from studies on bone marrow macrophages, 
have suggested that reacylation of liberated fatty acid back into 
the membrane lipid pool is an important control step in regulating 
free arachidonate levels. In that study, they demonstrated that 
para-chloromercuribenzoate (pCMB), a compound the same as pHMPSA 
in solution,inhibited the reacylation capacity suggesting perhaps 
that the acyl-transferase responsible is sulphydryl dependent. In 
this study the SH-dependence of acyltransferase enzymes was exam­
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ined by assaying the uptake of ^(H)-oleic acid.pHMPSA treatment 
was found to inhibit acylation in agreement with Kroner et al (1981) 
Furthermore, as with that study, the observed inhibition was trans­
ient and could be totally abrogated by thorough washing of the 
cells. The reason for this transient effect is not immediately 
clear. The acyltransferase is dependent upon co-enzyme A. Thus 
if the inhibition is due to its interaction with co-enzyme’s free 
SH group, turnover of co-enzyme during washing might cancel out the 
inhibition. It may be that control of levels of free arachidonic 
acid might be aberrant in rheumatoid monocytes in vivo where pres­
umably there is continual SH-oxidation. This could lead to in­
creased cyclo-oxygenase and lipoxygenase activity and consequently 
perturbed immunoregulation. Such a hypothesis to explain depressed 
in vitro immune responses by rheumatoid PBMCs, however, is ruled 
out by the inability of washing alone to alleviate defective rheum­
atoid cell function. In vivo, the actions of NSAIDs should effect­
ively inhibit cyclo-oxygenase activity/ which would seem to exclude 
a role for increased prostaglandin production in altered immuno­
regulation in rheumatoid patients. The effect of NSAIDs upon cyclo- 
oxygenase in rheumatoid cells would not be apparent in in vitro 
experiments since washing of the cells probably removes the drug. 
Experiments to assay the SH-dependence of phospholipase A^ activity 
per se were attempted but suffered from poor reproducibility making 
it impossible to draw any firm conclusions; however. Kroner and 
colleagues (1981) have demonstrated that in bone marrow macrophages, 
at least, phospholipase A^ activity was unaffected by pCMB treat­
ment.
Little is known about the role of lipoxygenase products in 
immunoregulation. Kelly et al (1979) demonstrated the ability of
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nor-dihydroguaiaretic acid (NDGA) and eicosatetraynoic acid 
(ETYA) to inhibit lectin-stimulated lymphocyte proliferation. These 
compounds are inhibitors of the lipoxygenase pathway suggesting 
that products of that pathway might be involved in production of 
proliferation. It is important to note that the inhibitory effects 
of NDGA and ETYA might also be mediated by their ability to inhibit 
thromboxane synthesis. However, the possible role of thromboxanes 
as immunoregulators is very poorly defined. Moreover, Kelly and 
colelagues have reported that inhibition of mitogenesis is more sens­
itive than thromboxane synthesis inhibition. The results in fig.26 
show that NDGA can inhibit IgG synthesis again suggesting the im­
portance of lipoxygenase products in immunoregulation. Caution is 
indicated in interpreting these results since not only can NDGA 
inhibit thromboxane production but at the concentration used in this 
study it may also have anti-oxidant activity. ETYA was not used 
in these experiments due to solubility problems. Maslen (1985) has 
shown that the lipoxygenase pathway might be sulphydryl dependent 
since pHMPSA blocks the production of lipoxygenase-derived perox­
ide (s). LTB^, the most stable lipoxygenase product, failed to re­
store the ability to synthesise IgG upon addition to cultures in 
which monocytes had been treated with pHMPSA. Although the inability 
to reverse inhibition might rule out the possibility that SH-block- 
ade inhibits the immune response by affecting lipoxygenase activ­
ity, it may be that other lipoxygenase products might achieve re­
versal of the inhibition. Alternatively, other concentrations of 
LTB^ might have been effective. Problems with obtaining adequate 
numbers of cells prevented use of more LTB^ concentrations Lipoxy­
genase activity in rheumatoid monocytes has not been measured and
so it is unclear whether an abnormality exists which might con­
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tribute to the aberrant in vitro immune response
As previously stated, NDGA inhibition of IgG synthesis 
might be due to its anti-oxidant activity. The contribution of 
oxygen derived radicals produced by monocytes to their interaction 
with lymphocytes is contentious. Novogrodsky et al (1982) have 
shown that hydroxyl radical scavengers inhibit lymphocyte mito­
genesis particularly when induced by phorbol myristate acetate 
(PMA), a monocyte-dependent mitogen. Gallagher and Curtis (1984) 
have shown that superoxide can enhance mitogenesis produced by some 
stimuli and can be mitogenic per se. Hydrogen peroxide has been 
shown to have both inhibitory and stimulatory effects upon mono­
nuclear cell responses. Metzger and colleagues (1980) demonstrated 
the ability of macrophage derived H^O^ and PGE^ to suppress mur­
ine cell proliferation. Lipsky (1984) has postulated that the 
immunosuppression exerted by D-penicillamine with copper ions in 
vitro is due to H^O^ suppression of T-lymphocyte activity. In 
contrast, Finazzo-Agro et al (1980) have shown H^O^ can be mito­
genic itself at low concentrations ( <  50 nM) in agreement with
the results produced in this study (fig.29). Similarly,Finazzi- 
Agro and colleagues showed that higher concentrations of 
( > 5 0 0  nM) are inhibitory again agreeing with the results here.
The possibility that enhanced H^O^ production by rheumatoid 
monocytes was responsible for depressed in vitro IgG synthesis was 
investigated by the addition of catalase to the cell cultures. 
Whilst catalase enhanced IgG synthesis in more patients than norm­
al subjects, this was not significant. Unfortunately, no parallel 
experiments were performed measuring the monocyte production.
Panayi (personal communication) from studies involving larger 
numbers of patients and controls has demonstrated that catalase
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can significantly increase lymphocyte proliferation in RA patients 
compared with controls.
Superoxide generation by monocytes is inhibited following SH 
blockade by pHMPSA (Table 10). This compound has previously been 
demonstrated to abolish superoxide production by neutrophils due to 
its interaction with surface SH groups (Tsan et al, 1976). It is 
possible that the inhibition is caused by interaction with the super­
oxide producing enzyme, NADPH oxidase which is known to be inhibited 
by high concentrations of pCMB in mouse macrophages (Berton et al, 
1982). Maslen (1985) has shown that H^O^production by both neutro­
phils and monocytes is abolished by treatment with pHMPSA. However, 
Tsan (1983) has indicated that whilst superoxide production is in­
hibited by pHMPSA, production is apparently unaffected. Since
most of the H^O^ is thought to be produced by dismutation of super­
oxide, this finding is somewhat surprising though it may be that 
H^O^ is produced by a mechanism independent of superoxide dismut- 
ation, in response to some stimuli, which is unaffected by SH- 
blockade.
Hydrogen peroxide was not able to reverse SH-blockade induced 
inhibition of IgG synthesis. As with the LTB^ experiments, it may 
be that is not the sole requirement needed to regenerate a
normal response. Another possible reason for this inability is that 
H^O^ may need to be specifically localised perhaps at a monocyte- 
lymphocyte "junction" which is not achieved by addition of exogen­
ous ^2^2’ This explanation similarly applies to the experiments 
where exogenous LTB^ was added to blocked cultures. Some experi­
ments were performed in which potassium superoxide was added in the 
same fashion as H^O^. Although the superoxide, as with H^O^, 
failed to reverse pHMPSA-induced inhibition (data not shown), too
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much emphasis should not be placed on the results because of the 
short half-life of the exogenous superoxide in neutral buffers. In 
contrast to Gallagher and Curtis (1984) no stimulation of IgG synth­
esis by superoxide was observed either in mitogen-free or mitogen- 
induced cultures. Again, the short half-life of exogenous super­
oxide might explain this difference.
The finding that monocyte oxidative metabolism is dependent 
upon free cell surface SH groups raised the possibility that def­
ective rheumatoid monocyte accessory function might be due to im­
paired oxidative metabolism due to surface SH-oxidation. However, 
monocytes from rheumatoid patients both on NSAIDs and on D-penicil­
lamine produced higher amounts of than control cells under un­
stimulated conditions and when stimulated with FMLP (although only 
unstimulated production was significantly different under the
Wilcoxon's ranking Sum test). The inability of 2-ME to alter 
^2^2 production by rheumatoid cells significantly suggests that ex­
cessive H^O^ production is independent of surface SH oxidation, a 
paradoxical conclusion perhaps in view of the inhibition produced 
by pHMPSA. Inhibition of oxidative metabolism by pHMPSA is probably 
mediated via interaction between the Hg moiety and SH groups where­
as rheumatoij cell surface SH oxidation is due to disulphide form­
ation probably with cysteine (Thomas and Evans, 1975). It is poss­
ible that mercury reacts with those SH groups involved in oxidative 
metabolism which are inaccessible to cysteine.
No significant difference was observed between production
by cells from patients on NSAIDs and those on D-penicillamine in 
this study. Hurst et al (1984) have shown that immunologically stim­
ulated monocytes from rheumatoid patients treated with D-penicilla­
mine show significantly enhanced rates of superoxide production compared
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to cells from patients on NSAIDs. Both groups of cells exhibited 
increased rates in comparison with normal cells when activated 
by immunological stimuli but not when unstimulated or when acti­
vated by biochemical stimuli. This latter observation, they sugg­
est, might indicate an effect of second-line drugs on expression 
of receptors such as Fc receptors. These results, together with 
other data they have produced (Hurst et al, 1982) indicate that 
D-penicillamine and sodium aurothiomalate treatment leads to en­
hanced monocyte responsiveness. The discrepancies between these 
results and those produced in this study where no differences in 
stimulated RA-NSAID and RA-D-penicillamine monocyte product­
ion were noted might be explained by the differences in stimuli 
used to elicit the oxidative response. FMLP stimulation is not 
mediated via Fc or C3b receptors but more likely via specific 
receptors which might be unaffected by D-penicillamine therapy. 
Another possible explanation may be dissimilarities in the dis­
ease activity of the patient groups selected in each study. En­
hanced spontaneous production by rheumatoid monocytes com­
pared to normals was not mirrored by increased rates of superoxide 
production by unstimulated rheumatoid monocytes in the studies by 
Hurst and colleagues. Disparity between patient selection might 
again account for this difference; however, it may suggest a 
superoxide independent H^O^-producing mecnahism in monocytes which 
is activated in rheumatoid disease.
It is unclear from the results produced in this study whether 
H^O^ production is progressively enhanced by D-penicillamine ther­
apy since H^O^ production was not assayed before commencement of 
therapy. It would be interesting to initiate a larger study to 
see if this was the case and to investigate whether responders 
and non-responders exhibited different oxidative metabolism profiles
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drug. Antigen presentation and Câ '*’ ion mobilisation by monocytes 
are not affected by SH-blockade by pHMPSA. Rheumatoid monocytes 
display activated oxidative metabolism and it may be that D-penicil­
lamine and other second line agents such as sodium aurothiomalate 
enhance this capacity still further. However, such an effect appears 
to be independent of the direct SH-reducing properties of the drug. 
Altered thiol expression may lead to abnormal regulation of free 
arachidonate leveDë and a direct effect upon cyclo-oxygenase and 
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APPENDICES








M.O. (M) 23 
FASTING







0 0 0 0 0 0 0 0 0 0
i.08 2.34 1.08 3.82 1.00 3.15 0.75 2.20 1.00 3.69
2.00 8.02 2.45 7.96 2.00 7.43 1.91 4.44 2.00 7.50
3.00 8.80 3.05 7.10 3.00 5.93 2.01 9.32 4.00 5.91
4.08 5.08 6.08 4.66 4.00 5.22 4.03 4.80 6.00 4.97
8.20 3.82 6.08 3.68 6.16 4.63 6.08 4.03 8.00 3.22
7.91 3.39 7.91 3.40 8.16 3.51 8.00 3.54 24.00 2.64
24.00 2.31 24.00 2.66 24.00 2.76 24.08 2.67
NON-FASTING NGN-FASTING NON-FAS'riNG NON-FASTING NON-FAS TING





0 0 0 0 0 • 0 0 0 0 0
1.00 3.00 1.08 3.32 1.00 2.04 1.03 2.43 1.10 2.50
2.00 8.00 2.08 5.74 2.00 5.33 2.00 6.56 2.00 4.04
3.00 5.37 3.05 4.14 3.00 4.08 3.33 5.77 3.06 3.69
4,00 4.60 3.95 3.77 4.00 3.67 4.08 4.44 4.00 2.98
8.16 3.59 8.05 3.37 6.00 3.38 6.00 3.55 8.00 2.58
8.00 3.15 7.75 3.17 8.00 3.14 8.00 3.03 24.50 2.32
24.00 2.21 ?4.00 2.53 24.00 2.66 24.00 2.49
APPENDIX 1 . Penicillamine plasma concentrations for 
normal volunteers (at times shown) in 
fasting and non-fasting conditions.








0 0 0 0 0 0 0 0 0 0
0.75 2.07 1.00 1.94 1.00 2.11 1.00 1.06 0.97 1.83
1.75 2.69 2.00 1.86 2.00 2.54 1.91 3.07 2.66 1.83
2.75 2.11 3.12 1.68 3.05 2.00 3.05 1.42 3.66 1.65
3.75 1.91 4.13 1.58 4.04 1.89 4.00 1.22 4.50 1.45
6.00 1.75 6.00 1.32 6.04 1.47 6.00 1.08 5.92 1.11
8.00 1.55 8.60 1.09 8.00 . 1.35 8.08 0.99 8.10 0.87
10.00 1.38 23.75 0.98 24.04* 1.60 23.75 0.84 23.92 0.73
24.00 1.11
P.N.{F) 62 J.H.(M) 43 0,S.(F) 72 P.H.(F) 69 J.C.(M 66
hrs (Open) hrs (D-pen)
fiqm\
hrs (Di>en) hrs hrs [D-pen)
0 0 0 0 0 • 0 0 0 0 0
0.7 2 .79 1.00 2.49 0.78 2.02 1.50 3.27 1.03 1.25
1.33 3.67 2.00 2.50 1.45. 2.89 2.50 2.84 2,00 2.18
2.03 3.50 3.00 2.21 2.13 3.11 4.50 2.00 4.05 1.75
2.53 2.76 4.66 1.87 2.70 2.27 3.30 1.31 6.04 1.39
4.05 2.61 6.00 1.58 6.08 1.78 24.00 1.08 7.75 1.31
7.83 2.18 8.00 1.52 Q.87 1.5Q 23.80 1.04
23.84 1.83 10.00 1.50 24.00 1.34
23.84 1.21
* 2nd 125mg. tablet administered 
at 23.45
APPENDIX 2 . Penicillamine plasma concentrations for
RA patients (at times shown).
O.r.(F) 62. E.J.(F) 77 H.H. (M) 68 L.H. (F) 57 O.G.(F) 46
hrs (D-pen)«gfmL hrs (D-pen)uQtrd.. hrs (Dpen)i/o/ml hrs (D-pen)-OS/ml. hrs (D-pen)MmL
0 0 0 0 0 0 0 0 0 0
1.00 0.95 1.00 1.30 1.00 ND 1.00 1.35 1.00 0.86
3.00 1.54 2.75 1.84 2.00 1.07 3.75 1.47 4.00 1.50
4.00 1.30 4.00 1.63 4.00 0.91 Q.OO 1.32 8.00 1.22
3.00 1.19 7.00 1.18 8.00 0.60
«•
26.00 41.58 24.00 0.75
















ND = none detected 
* = 2nd tablet administered
at 12.00 
** = 2nd tablet administered
at 24.00
APPENDIX 2. continued.
